register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00450203 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000536013"
]
},
{
"id_domain": "MRC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MRC-ST03"
]
},
{
"id_field": "secondary_id",
"id_value": [
"EU-20710"
]
},
{
... | https://clinicaltrials.gov/study/NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, c... | A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies | [
{
"description": "7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.",
"name": "bevacizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "dose banded as based on pat... | [
{
"design_group_description": "ECX + Bevacizumab",
"design_group_title": "ECX + Bevacizumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "7.5mg/kg IV Day 1 of each 21 cy... | [
"Oesophagogastric Cancer"
] | [
"The Medical Research Council"
] | [
"Roche Pharma AG",
"GSK Plc",
"Cancer Research UK"
] | [
[
{
"name": "二甲苯磺酸拉帕替尼",
"lang": "CN"
},
{
"name": "Lapatinib Ditosylate Hydrate",
"lang": "EN"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "4530ee903a254e9a88a8e8309594a0e9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ST03"
}
] |
NCT03107377 | [
{
"id_field": "org_study_id",
"id_value": [
"EVO-003"
]
}
] | https://clinicaltrials.gov/study/NCT03107377 | Phase 2B/3 Double-blinded Placebo-controlled | Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis infection | Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection | [
{
"description": "5 g dose applied up to 1 hour prior to coitus",
"name": "EVO100",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "5 g dose applied up to 1 hour prior to coitus",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c03841372... | [
{
"design_group_description": "A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.",
"design_group_title": "EVO100",
"design_group_type": "Active Co... | [
"Chlamydia Trachomatis Infection"
] | [
"Evofem, Inc."
] | [
"ICON Government & Public Health Solutions, Inc."
] | [
[
{
"name": "L-乳酸/柠檬酸/酒石酸氢钾",
"lang": "CN"
},
{
"name": "Citric Acid/Lactic Acid/Potassium Bitartrate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "455255a2384254088d5385d2ae299d4e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e832583233524de9eded39232e5e0523",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "AMP... |
NCT00869986 | [
{
"id_field": "org_study_id",
"id_value": [
"12791"
]
},
{
"id_field": "secondary_id",
"id_value": [
"I3E-BM-MSAE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2006-001947-70"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MBP82... | https://clinicaltrials.gov/study/NCT00869986 | A Study for Patients With Relapsing Remitting Multiple Sclerosis | The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis. | A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis | [
{
"description": "500mg, intravenous, every 6 months for 15 months",
"name": "dirucotide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY2820671",
"MBP8298"
],
"type": "Drug"
},
{
"description": "intravenous, once every six months for 15 months... | [
{
"design_group_title": "Dirucotide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "500mg, intravenous, every 6 months for 15 months",
"intervention_name": "dirucotide... | [
"Relapsing Remitting Multiple Sclerosis"
] | [
"Eli Lilly & Co."
] | [
"BioMS Technology Corp."
] | [
[
{
"name": "Dirucotide",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MINDSET01"
}
] |
NCT00027976 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000069099"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UAB-9833"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UAB-NQ401A4009"
]
},
{
"id_field": "secondary_id",
"id_value": [
"... | https://clinicaltrials.gov/study/NCT00027976 | Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent actinic keratoses.<br/>PURPOSE: Randomized phase II/III trial to determine the effectiveness of celecoxib in preventing skin cancer in patient... | A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses | [
{
"name": "celecoxib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "receipt of active drug",
"design_group_title": "Group 1 active arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "celecoxib",
"interventio... | [
"Precancerous Condition"
] | [
"The University of Alabama at Birmingham"
] | [
"National Cancer Institute"
] | [
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{
"name": "セレコキシブ",
"lang": "JP"
}
]
] | null |
NCT02919917 | [
{
"id_field": "org_study_id",
"id_value": [
"WEC-16-050"
]
}
] | https://clinicaltrials.gov/study/NCT02919917 | Treatment of Post-SCI Hypotension | While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters. Comprehensively documenting the impact of orthostatic hypotension (OH), regardless of symptoms, during acute rehabilitat... | Treatment of Post-SCI Hypotension: A Randomized Controlled Study of Usual Care Versus Anti Hypotension Therapy | [
{
"description": "Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d",
"name"... | [
{
"design_group_description": "Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.<br/>Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea... | [
"Spinal Cord Injury",
"Autonomic Dysreflexia",
"Orthostatic Hypotension",
"Baroreceptor Integrity",
"Sympathetic Integrity",
"Vagal Integrity",
"Hypotension",
"Cerebral Blood Flow",
"Blood Pressure",
"Venous Occlusion Plethysmography"
] | [
"James J. Peters Bronx Veterans Affairs Medical Center"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
[
{
"name": "盐酸米多君",
"lang": "CN"
},
{
"name": "Midodrine Hydrochloride",
"lang": "EN"
},
{
"name": "ミドドリン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00845364 | [
{
"id_field": "org_study_id",
"id_value": [
"RRK3217"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Eudract 2006-003164-62"
]
},
{
"id_field": "secondary_id",
"id_value": [
"REC 06/Q0104/141"
]
},
{
"id_field": "secondary_id",
"id_value":... | https://clinicaltrials.gov/study/NCT00845364 | Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery | Open-heart surgery causes injury of the heart muscle. Although this is usually mild, temporary and reversible, if it is severe it can endanger life and require additional high cost care. During surgery, techniques are used to protect the heart from injury, but these remain imperfect. This study assesses the effect of f... | Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery | [
{
"description": "Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.",
"name": "Perhexiline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PEXSIG"
],
"type": "Drug"
},
{
"description": "Tablets. Dose: 200m... | [
{
"design_group_description": "Pre-operative administration of Perhexiline tablets according to dosing schedule",
"design_group_title": "Perhexiline",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"in... | [
"Myocardial Reperfusion Injury",
"Cardiac Output, Low"
] | [
"University Hospitals Birmingham Charity"
] | [
"Brighton and Sussex University Hospitals NHS Trust",
"British Heart Foundation",
"University of Birmingham"
] | [
[
{
"name": "马来酸哌克昔林",
"lang": "CN"
},
{
"name": "Perhexiline Maleate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CASPER"
}
] |
NCT04139213 | [
{
"id_field": "org_study_id",
"id_value": [
"9919"
]
},
{
"id_field": "acronym",
"id_value": [
"MATPharm"
]
}
] | https://clinicaltrials.gov/study/NCT04139213 | Medication Maintenance Therapy in Community Pharmacy Settings | The goal of this study is to compare pharmacy-based medication assisted treatment (MAT) with usual care MAT for people with opioid use disorder. | Comparing Medication Maintenance in Comprehensive Community and Pharmacy Settings to Enhance Engagement | [
{
"description": "To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (su... | [
{
"design_group_description": "usual medication assisted treatment for maintenance care of opioid use disorder",
"design_group_title": "Usual care",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Opioid-use Disorder"
] | [
"Brown University Health"
] | [
"The Miriam Hospital",
"University of Rhode Island"
] | [
[
{
"name": "盐酸纳曲酮",
"lang": "CN"
},
{
"name": "Naltrexone Hydrochloride",
"lang": "EN"
}
],
[
{
"name": "丁丙诺啡纳洛酮",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride/Naloxone Hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MATPharm"
}
] |
NCT04817215 | [
{
"id_field": "org_study_id",
"id_value": [
"ORMD-0801-KHUH"
]
}
] | https://clinicaltrials.gov/study/NCT04817215 | Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | To compare the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by A1C in inadequately controlled T2DM subjects on diet control alone or on diet control and metformin monotherapy or two or three oral glucose-lowering agents.<br/>To assess the safety of repeat administration of ORMD-0801 in ina... | A Double-Blinded, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Uncontrolled Type 2 DM Subjects on Diet Control Alone, Metformin Monotherapy, or Two or Three Oral Glucose-lowering Agents | [
{
"description": "Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo",
"name": "ORMD-0801",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Patients who are Drug naïve or diet controlled",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or ... | [
"Diabetes Mellitus, Type 2"
] | [
"King Hamad General Hospital"
] | [
"Royal College of Surgeons in Ireland - Medical University of Bahrain",
"Oramed Ltd."
] | [
[
{
"name": "重组人胰岛素（Oramed）",
"lang": "CN"
},
{
"name": "Insulin (Oramed)",
"lang": "EN"
}
]
] | null |
NCT00322101 | [
{
"id_field": "org_study_id",
"id_value": [
"1992.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2010-00737"
]
},
{
"id_field": "secondary_id",
"id_type": ... | https://clinicaltrials.gov/study/NCT00322101 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | RATIONALE: Giving chemotherapy, such as fludarabine phosphate, busulfan, and cyclophosphamide, and total-body radiation therapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem ... | A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | [
{
"description": "Radiation",
"name": "total-body irradiation",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"other_name": [
"TBI"
],
"type": "Radiation"
},
{
"description": "Undergo allogeneic transplantation",
"name": "allogeneic hematopoietic stem cell transpla... | [
{
"design_group_description": "CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.<br/>TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.<br/>GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients rece... | [
"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",
"Acute Myeloid Leukemia/Transient Myeloproliferative Disorder",
"Adult Acute Myeloid Leukemia in Remission",
"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
"Adult Acute Myeloid Leukemia With Del(5q)",
... | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Heart, Lung & Blood Institute",
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT00080314 | [
{
"id_field": "org_study_id",
"id_value": [
"CN138-096"
]
}
] | https://clinicaltrials.gov/study/NCT00080314 | Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode | The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode | [
{
"description": "Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.",
"name": "Aripiprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abilify"
],
"type": "Drug"
},
{
"description": "Tablets, Oral, 0 mg, Once daily, 8 weeks.",
"name": ... | [
{
"design_group_title": "A1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.",
"intervention_name": "Arip... | [
"Bipolar Disorder"
] | [
"Otsuka Pharmaceutical Development & Commercialization, Inc."
] | [
"Otsuka America Pharmaceutical, Inc."
] | [
[
{
"name": "阿立哌唑",
"lang": "CN"
},
{
"name": "Aripiprazole",
"lang": "EN"
},
{
"name": "アリピプラゾール水和物",
"lang": "JP"
}
]
] | null |
NCT00190645 | [
{
"id_field": "org_study_id",
"id_value": [
"2688"
]
},
{
"id_field": "secondary_id",
"id_value": [
"F1J-MC-SBAW"
]
}
] | https://clinicaltrials.gov/study/NCT00190645 | To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence | The patients are being followed in this study to determine the safety of taking the medication Duloxetine for a long period of time. The patients participating in this study suffer from Stress Urinary Incontinence. | Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence | [
{
"name": "Duloxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Stress Urinary Incontinence"
] | [
"Eli Lilly & Co."
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "盐酸度洛西汀",
"lang": "CN"
},
{
"name": "Duloxetine Hydrochloride",
"lang": "EN"
},
{
"name": "デュロキセチン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT04329611 | [
{
"id_field": "org_study_id",
"id_value": [
"ABCOV-01 version 1.5"
]
}
] | https://clinicaltrials.gov/study/NCT04329611 | ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease | Albertans with COVID-19 are at risk of deteriorating and developing severe illness. Those over age 40 or with co-morbid illness, and likely those who are immune suppressed, are at highest risk. This study will include a focus on people with immune-suppressed states. Individuals confirmed to have SARS-CoV-2 infection wi... | A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease. | [
{
"description": "COVID19",
"name": "Hydroxychloroquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"plaquenil"
],
"type": "Drug"
}
] | [
{
"design_group_description": "hydroxychloroquine 400 mg po bid loading dose for 1 day followed by 200 mg po twice daily for 4 days",
"design_group_title": "hydroxychloroquine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"inte... | [
"COVID-19"
] | [
"University of Calgary"
] | [
"Province of Alberta",
"Alberta Innovates",
"Calgary Health Trust",
"University of Calgary",
"University of Alberta",
"Alberta Health Services"
] | [
[
{
"name": "硫酸羟氯喹",
"lang": "CN"
},
{
"name": "Hydroxychloroquine Sulfate",
"lang": "EN"
},
{
"name": "ドロキシクロロキン硫酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "28a83ea3892230aae5a848252382e200",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Alberta HOPE COVID-19 trial"
},
{
"identifier_source": [
{
"code": "ee5a822a804a8a8455e59e5a03a84422",
"s... |
NCT04022967 | [
{
"id_field": "org_study_id",
"id_value": [
"ANRS 12372 MODERATO"
]
},
{
"id_field": "acronym",
"id_value": [
"MODERATO"
]
}
] | https://clinicaltrials.gov/study/NCT04022967 | ANRS 12372 MODERATO Study | MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).<br/>HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed will be recruited and followed during 100 weeks.<b... | Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+T... | [
{
"description": "One daily tablet (50mg) during 96 weeks",
"name": "dolutegravir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks",
"name": "atazanavir b... | [
{
"design_group_title": "Arm 1 : Dual maintenance therapy DTG+3TC",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "One daily tablet (300mg) during 96 weeks",
"intervent... | [
"HIV-1-infection"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Mylan Laboratories Ltd."
] | [
[
{
"name": "多替拉韦钠",
"lang": "CN"
},
{
"name": "Dolutegravir Sodium",
"lang": "EN"
},
{
"name": "ドルテグラビルナトリウム",
"lang": "JP"
}
],
[
{
"name": "硫酸阿扎那韦/利托那韦",
"lang": "CN"
},
{
"name": "Atazanavir Sulfate/Ritonavir",
"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ANRS 12372 MODERATO"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MODERATO"
}
] |
NCT01324128 | [
{
"id_field": "org_study_id",
"id_value": [
"PA-CL-05A"
]
}
] | https://clinicaltrials.gov/study/NCT01324128 | A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients | This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate levels in these patients. | An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia | [
{
"description": "Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).",
"name": "PA21 (2.5 g tablet containing 500 mg iron)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (1... | [
{
"design_group_title": "PA21 (2.5 g tablet)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).",
"... | [
"Chronic Kidney Disease Requiring Chronic Dialysis"
] | [
"Corden Pharma Fribourg SA"
] | [
"Fresenius Medical Care North America Holdings LP"
] | [
[
{
"name": "蔗糖铁",
"lang": "CN"
},
{
"name": "Iron sucrose",
"lang": "EN"
},
{
"name": "スクロオキシ水酸化鉄",
"lang": "JP"
}
]
] | null |
NCT00259974 | [
{
"id_field": "org_study_id",
"id_value": [
"P040409"
]
}
] | https://clinicaltrials.gov/study/NCT00259974 | RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy | Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug wh... | Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy | [
{
"description": "Rituximab",
"name": "Rituximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Rituximab",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Rituximab",
"intervention_name": "Rituximab",
... | [
"Polyneuropathy"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Centre Hospitalier Universitaire Pitie-Salpetriere",
"Hospices Civils de Lyon",
"Centre hospitalier universitaire Henri-Mondor",
"Centre Hospitalier Universitaire de Limoges",
"Universitätsspital Basel"
] | [
[
{
"name": "利妥昔单抗",
"lang": "CN"
},
{
"name": "Rituximab",
"lang": "EN"
},
{
"name": "リツキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00002527 | [
{
"id_field": "org_study_id",
"id_value": [
"CALGB-9270"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CLB-9270"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-C9270"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCCTG-9492... | https://clinicaltrials.gov/study/NCT00002527 | Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin may be an effective way to prevent the recurrence of polyps in colorectal cancer.<br/>PURPOSE: Randomized phase III trial to study the effectiveness of aspirin in treating patient... | Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study | [
{
"name": "aspirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | [
{
"design_group_description": "325 mg/day PO",
"design_group_title": "Aspirin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "aspirin",
"intervention_type": "Drug",
... | [
"Colorectal Cancer"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute"
] | [
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル酸",
"lang": "JP"
}
]
] | null |
NCT00765817 | [
{
"id_field": "org_study_id",
"id_value": [
"H8O-US-GWCO"
]
}
] | https://clinicaltrials.gov/study/NCT00765817 | Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone. | A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications | [
{
"description": "subcutaneous injection, twice a day",
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "subcutaneous injection, twice a day, 10mcg",
"name": "exenatide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_title": "1",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "subcutaneous injection, twice a day",
"intervention_name": "placebo",
"interve... | [
"Type 2 Diabetes"
] | [
"AstraZeneca PLC"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "艾塞那肽",
"lang": "CN"
},
{
"name": "Exenatide",
"lang": "EN"
},
{
"name": "エキセナチド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "e2daee9a99a85425e2e3258e2099a825",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BEGIN Once Long"
}
] |
NCT02135042 | [
{
"id_field": "org_study_id",
"id_value": [
"NRG-HN001"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2023-06678"
]
},
{
"id_domain": "NRG Oncology",
"id_fiel... | https://clinicaltrials.gov/study/NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. Whe... | Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | [
{
"description": "Given IV",
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abiplatin",
"Blastolem",
"Briplatin",
"CDDP",
"Cis-diammine-dichloroplatinum",
"Cis-diamminedichloridoplatinum",
"Cis-diamminedichloro P... | [
{
"design_group_description": "Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.... | [
"Epstein-Barr Virus Infection",
"Stage II Nasopharyngeal Carcinoma",
"Stage III Nasopharyngeal Carcinoma",
"Stage IVA Nasopharyngeal Carcinoma",
"Stage IVB Nasopharyngeal Carcinoma"
] | [
"NRG Oncology"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
... | null |
NCT04220190 | [
{
"id_field": "org_study_id",
"id_value": [
"RAPA-501-ALS"
]
}
] | https://clinicaltrials.gov/study/NCT04220190 | RAPA-501 Therapy for ALS | RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS). | Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis | [
{
"description": "Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)",
"name": "RAPA-501 Autologous T stem cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"RAPA-501 cells"
],
"... | [
{
"design_group_description": "Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)",
"design_group_title": "RAPA-501 Autologous T stem cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f3... | [
"Amyotrophic Lateral Sclerosis"
] | [
"Rapa Therapeutics LLC"
] | [
"The General Hospital Corp."
] | [
[
{
"name": "RAPA-501",
"lang": "EN"
}
]
] | null |
NCT03614494 | [
{
"id_field": "org_study_id",
"id_value": [
"UW18-003"
]
}
] | https://clinicaltrials.gov/study/NCT03614494 | Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception | This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured ... | Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial | [
{
"description": "Additional co-treatment",
"name": "Piroxicam 40 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Standard treatment",
"name": "Levonorgestrel 1.5mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "D... | [
{
"design_group_description": "Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose",
"design_group_title": "Piroxicam",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interven... | [
"Emergency Contraception"
] | [
"The University of Hong Kong"
] | [
"The Family Planning Association of Hong Kong"
] | [
[
{
"name": "左炔诺孕酮",
"lang": "CN"
},
{
"name": "Levonorgestrel",
"lang": "EN"
},
{
"name": "レボノルゲストレル",
"lang": "JP"
}
],
[
{
"name": "吡罗昔康",
"lang": "CN"
},
{
"name": "Piroxicam",
"lang": "EN"
},
{
"na... | null |
NCT04313088 | [
{
"id_field": "org_study_id",
"id_value": [
"26347"
]
}
] | https://clinicaltrials.gov/study/NCT04313088 | Investigation of Eluxadoline for Diabetic Diarrhea | Diabetes is a chronic disease that affects a large part of the United States population. The majority of patients with diabetes will experience gastrointestinal symptoms. One of the most troublesome gastrointestinal symptoms that diabetes can cause is diarrhea, otherwise known as "Diabetic Diarrhea." This occurs becaus... | Double Blind, Placebo Controlled, Cross Over Study to Investigate the Effectiveness and Safety of Eluxadoline in the Treatment of Diabetic Diarrhea | [
{
"description": "Eluxadoline 100mg by mouth twice daily with food",
"name": "Eluxadoline 100 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Viberzi"
],
"type": "Drug"
}
] | [
{
"design_group_description": "All eligible patients will receive both eluxadoline and placebo, however each patient will be randomized to the order in which this happens. Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily then matching placebo o... | [
"Diabetic Diarrhea",
"Diabetes",
"Diarrhea"
] | [
"Temple University Graduate School"
] | [
"Allergan UC"
] | [
[
{
"name": "艾沙度林",
"lang": "CN"
},
{
"name": "Eluxadoline",
"lang": "EN"
}
]
] | null |
NCT05313958 | [
{
"id_field": "org_study_id",
"id_value": [
"2021-KY-052"
]
},
{
"id_domain": "Province natural science fund of Guangdong",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"2021A1515011809"
]
},
{
"id_field": "acronym",
"... | https://clinicaltrials.gov/study/NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-202... | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China | [
{
"description": "5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine",
"name": "Cladribine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"cladribine injection"
],
"type": "Drug"
},
{
"description": "5ug/kg/day d0-5,if Peripheral blood leukocytes<... | [
{
"design_group_description": "The patients in this arm will receive SCCLG-M5 2022 regimen for newly dignosed acute monocytic leukemia (M5) ,including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period and followed by three courses(HA1M, HA2E, HA3) in consolidation therapy prescri... | [
"Leukemia, Monocytic, Acute",
"Pediatric AML"
] | [
"Sun Yat-Sen Memorial Hospital"
] | [
"Guangzhou First People's Hospital",
"Xiangya Hospital Central South University",
"Foshan Maternity and Child Health Care Hospital",
"Southern Medical University",
"The Third Affiliated Hospital, Sun Yat-Sen University",
"The First Affiliated Hospital of Nanchang University",
"The First Affiliated Hospi... | [
[
{
"name": "克拉屈滨",
"lang": "CN"
},
{
"name": "Cladribine",
"lang": "EN"
},
{
"name": "クラドリビン",
"lang": "JP"
}
],
[
{
"name": "盐酸米托蒽醌",
"lang": "CN"
},
{
"name": "Mitoxantrone Hydrochloride",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SCCLG-M5"
}
] |
NCT04236830 | [
{
"id_field": "org_study_id",
"id_value": [
"SDF/potassium iodide"
]
}
] | https://clinicaltrials.gov/study/NCT04236830 | Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars | The aim of this study is to evaluate and compare the clinical effectiveness of 38% silver diamine fluoride with and without potassium iodide with that of resin modified glass ionomer cement in indirect pulp capping of young permanent molars. | Effectiveness of Silver Diamine Fluoride/ Potassium Iodide in Indirect Pulp Capping of Young Permanent Molars (a Randomized Controlled Clinical Trial) | [
{
"description": "Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.",
"name": "Silver diamine fluoride/ potassium iodide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SDF/KI"
],
"type": "Drug"
},
{
"descr... | [
{
"design_group_description": "Riva Star Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia",
"design_group_title": "Silver diamine fluoride/ potassium iodide group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Tertiary Dentine",
"Indirect Pulp Capping"
] | [
"Alexandria University"
] | [
"Alexandria University"
] | [
[
{
"name": "碘化钾",
"lang": "CN"
},
{
"name": "Potassium Iodide",
"lang": "EN"
}
],
[
{
"name": "银氮烷氟化物",
"lang": "CN"
},
{
"name": "Silver Diammine Fluoride",
"lang": "EN"
},
{
"name": "フッ化ジアンミン銀",
"lang": "JP"
}... | null |
NCT00327444 | [
{
"id_field": "org_study_id",
"id_value": [
"EFC6125"
]
},
{
"id_field": "secondary_id",
"id_value": [
"EudraCT : 2005-005026-31"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AVE0005A /3001"
]
}
] | https://clinicaltrials.gov/study/NCT00327444 | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.<br/>Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in particip... | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | [
{
"description": "4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.",
"name": "aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Pla... | [
{
"design_group_description": "Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.<br/>In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.",
"design_group_title": "Placebo",
"design_group_type": "Pl... | [
"Ovarian Neoplasms",
"Ascites"
] | [
"Sanofi"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04297683 | [
{
"id_field": "org_study_id",
"id_value": [
"2019P003518"
]
}
] | https://clinicaltrials.gov/study/NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. | HEALEY ALS Platform Trial | [
{
"description": "Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight",
"name": "Zilucoplan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Drug: Ver... | [
{
"design_group_description": "Participants are randomized to receive either active zilucoplan or matching placebo.<br/>NO LONGER RECRUITING; RESULTS REPORTED.",
"design_group_title": "Regimen A - Zilucoplan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35448... | [
"Amyotrophic Lateral Sclerosis"
] | [
"The General Hospital Corp."
] | [
"The General Hospital Corp."
] | [
[
{
"name": "Verdiperstat",
"lang": "EN"
}
],
[
{
"name": "海藻糖",
"lang": "CN"
},
{
"name": "Trehalose",
"lang": "EN"
}
],
[
{
"name": "泽卢克布仑钠",
"lang": "CN"
},
{
"name": "Zilucoplan",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"code": "2e5ae34e224a5224a22a23a8a888532a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "5d85a52d8e088428e2522908d852d85e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT00514995 | [
{
"id_field": "org_study_id",
"id_value": [
"McElroy"
]
}
] | https://clinicaltrials.gov/study/NCT00514995 | Sodium Oxybate in the Treatment of Binge Eating Disorder | The purpose of this research study is to study the effectiveness, tolerability and safety of sodium oxybate in outpatients with binge eating disorder. | null | [
{
"description": "4.5 g/night - 9 g/night, liquid taken twice per night",
"name": "Sodium Oxybate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "4.5 g/night - 9 g/night, liquid taken twice per night",
"intervention_name": "Sodium Oxybate... | [
"Binge Eating Disorder"
] | [
"The Craig & Frances Lindner Center of Hope"
] | [
"Jazz Pharmaceuticals Plc"
] | [
[
{
"name": "羟丁酸钠",
"lang": "CN"
},
{
"name": "Sodium Oxybate",
"lang": "EN"
}
]
] | null |
NCT04244006 | [
{
"id_field": "org_study_id",
"id_value": [
"RC31/19/0045"
]
},
{
"id_field": "acronym",
"id_value": [
"NS-DUPI"
]
}
] | https://clinicaltrials.gov/study/NCT04244006 | A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome | To date, there are no effective therapy for the management of Netherton Syndrome (NS) Patients use emollients with a limited efficacy on scaling and no efficacy on skin inflammation and pruritus. They may also use topical corticosteroids or calcineurin inhibitors in case of eczematous lesions. The use of therapies targ... | A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome | [
{
"description": "administration of dupilumab corresponding to dupilumab arm",
"name": "Dupilumab Prefilled Syringe",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "administration of placebo corresponding to placebo arm",
"name": "Placebo Prefi... | [
{
"design_group_description": "The patient will receive 2 doses at baseline and then 1 dose every 2 weeks (8 administrations in total) of Dupilumab 300 mg (syringe of 2 mL for subcutaneous administration).",
"design_group_title": "Dupilumab",
"design_group_type": "Experimental",
"design_group_type_n... | [
"Netherton Syndrome"
] | [
"Toulouse University Hospital"
] | [
"Medsharing"
] | [
[
{
"name": "度拉糖肽",
"lang": "CN"
},
{
"name": "Dulaglutide",
"lang": "EN"
},
{
"name": "デュラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NS-DUPI"
}
] |
NCT01662882 | [
{
"id_field": "org_study_id",
"id_value": [
"18F-AV-45-J05"
]
},
{
"id_domain": "Eli Lilly Japan",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"I6E-AV-AVBB"
]
}
] | https://clinicaltrials.gov/study/NCT01662882 | A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) | Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI). | An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) | [
{
"description": "IV injection, 370 MBq(10mCi), single dose",
"name": "florbetapir (18F)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"18F-AV-45",
"Amyvid",
"Florbetapir F 18"
],
"type": "Drug"
}
] | [
{
"design_group_title": "AD Subjects",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "IV injection, 370 MBq(10mCi), single dose",
"intervention_name": "florbetapir (18F... | [
"Alzheimer's Disease",
"Mild Cognitive Impairment"
] | [
"Avid Radiopharmaceuticals, Inc."
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "氟贝他吡[18F]",
"lang": "CN"
},
{
"name": "Florbetapir F-18",
"lang": "EN"
},
{
"name": "フロルベタピル（１８Ｆ）",
"lang": "JP"
}
]
] | null |
NCT04098302 | [
{
"id_field": "org_study_id",
"id_value": [
"19-147-2"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P50AA027055"
]
}
] | https://clinicaltrials.gov/study/NCT04098302 | Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy | The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing drinking and heavy drinking in men and women with alcohol use disorder. The investigators hypothesize that dutasteride 1 mg per day will be well tolerated in this patient population and that, compared to placebo treatment, dutas... | Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy | [
{
"description": "1 mg/day oral dutasteride (2 x 0.5 mg capsules)",
"name": "Dutasteride Capsules",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Avodart"
],
"type": "Drug"
},
{
"description": "Placebo capsules with matching appearance as Dutasteride C... | [
{
"design_group_description": "two 0.5 mg capsules of dutasteride daily",
"design_group_title": "dutasteride",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "1 mg/day ... | [
"Alcohol Use Disorder"
] | [
"University of Connecticut Health Center"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "度他雄胺",
"lang": "CN"
},
{
"name": "Dutasteride",
"lang": "EN"
},
{
"name": "デュタステリド",
"lang": "JP"
}
]
] | null |
NCT00296972 | [
{
"id_field": "org_study_id",
"id_value": [
"ML 18562A"
]
}
] | https://clinicaltrials.gov/study/NCT00296972 | Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication | The main purpose of this study is to compare the safety, effectiveness and tolerability of using Pegasys with Copegus in people who have both the hepatitis C virus (HCV) genotype 1 and HIV who continue taking HAART (highly active antiretroviral therapy) to those who discontinue taking HAART.<br/>Canadian guidelines rec... | A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART | [
{
"name": "peg interferon plus ribavirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "Drug"
}
] | null | [
"Chronic Hepatitis C",
"HIV Infections"
] | [
"University Health Network"
] | [
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "培集成干扰素α-2 (北京凯因)",
"lang": "CN"
},
{
"name": "Peginterferon Alfacon-2(Beijing Kawin Technology)",
"lang": "EN"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "リバビリン",... | null |
NCT03554031 | [
{
"id_field": "org_study_id",
"id_value": [
"GenSci PWS CT"
]
}
] | https://clinicaltrials.gov/study/NCT03554031 | A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome | To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS. | A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome | [
{
"description": "Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.",
"name": "Recombinant Human Growth Hormone (rhGH) Injection",
"n... | [
{
"design_group_description": "Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.",
"design_group_title": "rhGH injection/Jintr... | [
"Prader-Willi Syndrome"
] | [
"Changchun Genescience Pharmaceuticals Co., Ltd."
] | [
"Tongji Medical College of Huazhong University of Sci & Tech",
"Peking Union Medical College Hospital",
"The Children's Hospital of Zhejiang University School of Medicine",
"Beijing Children Hospital Group Co. Ltd.",
"Peking University First Hospital",
"Paediatrics Hospital Affiliated To Fudan University"... | [
[
{
"name": "重组人生长激素(长春金赛)",
"lang": "CN"
},
{
"name": "Recombinant human growth hormone(Changchun Genescience)",
"lang": "EN"
}
]
] | null |
NCT04496245 | [
{
"id_field": "org_study_id",
"id_value": [
"BV-2020/19"
]
},
{
"id_field": "acronym",
"id_value": [
"COVIDRASP"
]
}
] | https://clinicaltrials.gov/study/NCT04496245 | Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85 | Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia.<br/>Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.<br... | Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85 | [
{
"description": "Broncho-Vaxom adult capsules® (OM85)",
"name": "Broncho-Vaxom®",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"OM85"
],
"type": "Drug"
}
] | [
{
"design_group_description": "One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.",
"design_group_title": "Wait-list control",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e... | [
"Respiratory Viral Infection",
"Covid19"
] | [
"The University of Queensland"
] | [
"Griffith University",
"Telethon Kids Institute",
"The Prince Charles Hospital"
] | [
[
{
"name": "细菌溶解产物",
"lang": "CN"
},
{
"name": "Bacterial Lysates ( OM Pharma)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COVIDRASP"
}
] |
NCT04606563 | [
{
"id_field": "org_study_id",
"id_value": [
"H20-01984"
]
},
{
"id_field": "acronym",
"id_value": [
"ARBs CORONA II"
]
}
] | https://clinicaltrials.gov/study/NCT04606563 | Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? | SARS-CoV-2 is a member of a class of viruses: angiotensin converting enzyme 2 (ACE2)-binding viruses that study calls "ABVs". The World Health Organization (WHO) and others are performing randomized controlled trials (RCTs) of vaccines and novel antivirals to address SARS-CoV-2 directly. However, the critical illness c... | Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? | [
{
"description": "Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.",
"name": "Losartan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cozaar"
],
"type": "Drug"
},
{
"description": "Oral Valsartan 40 mg, stepped u... | [
{
"design_group_description": "Patients will initially receive initial dose of oral ARBs, increased to higher dose after 24 hours and then increased to a max dose after another 24 hours, dependent on tolerance. Patient will remain at dose for duration of hospital (max of 3 months if still hospitalized). Toleran... | [
"Covid19",
"SARS-CoV Infection"
] | [
"University of British Columbia"
] | [
"Canadian Institutes of Health Research"
] | [
[
{
"name": "厄贝沙坦",
"lang": "CN"
},
{
"name": "Irbesartan",
"lang": "EN"
},
{
"name": "イルベサルタン",
"lang": "JP"
}
],
[
{
"name": "坎地沙坦酯",
"lang": "CN"
},
{
"name": "Candesartan Cilexetil",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ARBs CORONA II"
}
] |
NCT06203210 | [
{
"id_field": "org_study_id",
"id_value": [
"DS7300-188"
]
},
{
"id_domain": "EU CT",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2023-509628-16-00"
]
},
{
"id_domain": "jRCT",
"id_field": "secondary_id",
"id_type": "Other... | https://clinicaltrials.gov/study/NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC). | A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02) | [
{
"description": "12 mg/kg intravenous dose on Day 1 of each 21-day cycle",
"name": "Ifinatamab deruxtecan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"I-DXd"
],
"type": "Drug"
},
{
"description": "Topotecan will be administered per local SoC.",
... | [
{
"design_group_description": "Participants randomized to receive 12 mg/kg I-DXd monotherapy on Day 1 of each 21-day cycle until unacceptable toxicity, progressive disease (PD), or withdrawal of consent as specified in the protocol.",
"design_group_title": "Ifinatamab deruxtecan (I-DXd)",
"design_group_... | [
"Small Cell Lung Cancer"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "Ifinatamab deruxtecan",
"lang": "EN"
},
{
"name": "イフィナタマブ デルクステカン（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "24d98d442ae4ed49a089882e3e9852e8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "IDeate-Lung02"
}
] |
NCT00205842 | [
{
"id_field": "org_study_id",
"id_value": [
"3753-001"
]
},
{
"id_domain": "Sponsor protocol number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"14CL314"
]
}
] | https://clinicaltrials.gov/study/NCT00205842 | Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | Patients undergoing major abdominal surgery are at highest risk for developing Postoperative Ileus (POI), occurring in nearly all cases. Signs and symptoms of POI may include abdominal distention and bloating, persistent abdominal pain; nausea and/or vomiting; variable reduction of bowel sounds; delayed passage of or i... | A Phase IIIb, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus | [
{
"name": "alvimopan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Ileus"
] | [
"Cubist Pharmaceuticals LLC"
] | [
"GSK Plc"
] | [
[
{
"name": "爱维莫潘",
"lang": "CN"
},
{
"name": "Alvimopan Dihydrate",
"lang": "EN"
}
]
] | null |
NCT01633099 | [
{
"id_field": "org_study_id",
"id_value": [
"DACOGENAML2003"
]
}
] | https://clinicaltrials.gov/study/NCT01633099 | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | The purpose of this study is to confirm the safety and the therapeutic effect of Decitabine in the treatment of elderly Acute Myeloid Leukemia (AML) patients. | The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients | [
{
"description": "1. Number of Cycles: 4 cycles.<br/>2. Dose and drug delivery(decitabine):<br/>The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.<br/>If bone marrow blast cells<5%, the following cy... | [
{
"design_group_description": "Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.",
"design_group_title": "Decitabine, CR rate,OS,EFS,RFS",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "1. Num... | [
"Untreated Adult Acute Myeloid Leukemia",
"Effect of Drugs",
"Drug Safety"
] | [
null
] | [
"Xian-Janssen Pharmaceutical Ltd."
] | [
[
{
"name": "地西他滨",
"lang": "CN"
},
{
"name": "Decitabine",
"lang": "EN"
}
]
] | null |
NCT03515629 | [
{
"id_field": "org_study_id",
"id_value": [
"R2810-ONC-16111"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-001041-27"
]
}
] | https://clinicaltrials.gov/study/NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet chemotherapy plus ipilimumab combination therapy (hereinafter referred to ... | A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥5... | [
{
"description": "REGN2810 plus ipilimumab",
"name": "REGN2810/ipi",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"cemiplimab"
],
"type": "Drug"
},
{
"description": "REGN2810 plus chemotherapy plus Ipilimumab",
"name": "REGN2810/chemo/ipi",
"no... | [
{
"design_group_description": "Pembrolizumab",
"design_group_title": "Pembrolizumab",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Reference drug administered IV inf... | [
"Non-small Cell Lung Cancer"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
"Sanofi"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "塞普利单抗",
"lang": "CN"
},
{
"name": "Cemiplimab-RWLC",
"lang": "EN"
},
{
... | null |
NCT03073967 | [
{
"id_field": "org_study_id",
"id_value": [
"AIC316-03-II-01"
]
},
{
"id_field": "acronym",
"id_value": [
"PRIOH-1"
]
}
] | https://clinicaltrials.gov/study/NCT03073967 | Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects | Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state... | A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1) | [
{
"description": "100 mg oral tablets",
"name": "Pritelivir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 ... | [
{
"design_group_description": "Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days",
"design_group_title": "Part C, Pritelivir",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f... | [
"HSV Infection"
] | [
"Aicuris Anti-Infective Cures AG"
] | [
"Medpace, Inc."
] | [
[
{
"name": "普利特利韦",
"lang": "CN"
},
{
"name": "Pritelivir",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "42599a8a35829e24a8ae2358e4008255",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a853ae5e8eed9d9e8a232dd442229232",
"s... |
NCT02210325 | [
{
"id_field": "org_study_id",
"id_value": [
"CE01-302"
]
},
{
"id_domain": "NIAID",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"15-0091, HHSN272201300013"
]
},
{
"id_field": "acronym",
"id_value": [
"SOLITAIRE-... | https://clinicaltrials.gov/study/NCT02210325 | Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea | This study will compare a single dose of oral solithromycin to the standard of care (intramuscular ceftriaxone plus oral azithromycin) in the treatment of patients with urogenital gonorrhea. A completed open-label Phase 2 study with single doses of solithromycin resulted in 100% microbiological eradication in male and ... | An Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of Oral Solithromycin Compared to Single-Dose Intramuscular Ceftriaxone Plus Single-Dose Oral Azithromycin in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea With or Without Concomitant C... | [
{
"name": "solithromycin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "ceftriaxone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "azithromycin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin",
"design_group_title": "Ceftriaxone plus Azithromycin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
... | [
"Uncomplicated Urogenital Gonorrhea"
] | [
"Melinta Therapeutics, Inc."
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "索利霉素",
"lang": "CN"
},
{
"name": "Solithromycin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SOLITAIRE-U"
}
] |
NCT00931528 | [
{
"id_field": "org_study_id",
"id_value": [
"RTOG 0831"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CDR0000647146"
]
},
{
"id_domain": "CTRP (Clinical Trials Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value... | https://clinicaltrials.gov/study/NCT00931528 | Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy | RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction.<br/>PURPOSE: This randomized phase III trial is studying tadalafil to ... | A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer | [
{
"description": "Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.",
"name": "Tadalafil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Beginning ≤ 7 days after the start of radiother... | [
{
"design_group_description": "Tadalafil",
"design_group_title": "Tadalafil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Beginning ≤ 7 days after the start of radiother... | [
"Prostate Cancer",
"Sexual Dysfunction"
] | [
"Radiation Therapy Oncology Group"
] | [
"National Cancer Institute",
"NRG Oncology"
] | [
[
{
"name": "他达拉非",
"lang": "CN"
},
{
"name": "Tadalafil",
"lang": "EN"
},
{
"name": "タダラフィル",
"lang": "JP"
}
]
] | null |
NCT03669484 | [
{
"id_field": "org_study_id",
"id_value": [
"CN01082020"
]
}
] | https://clinicaltrials.gov/study/NCT03669484 | Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia | The purpose of this study was to perform comparative evaluation of clinical efficacy and safety of Remimazolam and Propofol for induction and maintenance of general anesthesia in patients undergoing elective surgery under general anaesthesia. | International Multicenter Single Blind Randomized Clinical Study to Compare Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgical Procedures Under General Anesthesia | [
{
"description": "Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)",
"name": "Remimazolam",
"normalized_type": "3d1aa88261d64c038413... | [
{
"design_group_description": "The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.<br/>Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitor... | [
"General Anaesthesia"
] | [
"R-Pharm JSC"
] | [
"Synergy Research Group, Inc."
] | [
[
{
"name": "枸橼酸芬太尼",
"lang": "CN"
},
{
"name": "Fentanyl Citrate",
"lang": "EN"
},
{
"name": "フェンタニルクエン酸塩",
"lang": "JP"
}
],
[
{
"name": "甲苯磺酸瑞马唑仑",
"lang": "CN"
},
{
"name": "Remimazolam Tosylate",
"lang": "EN"
... | null |
NCT04661358 | [
{
"id_field": "org_study_id",
"id_value": [
"DRCR.net Protocol AF"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U10EY014231"
]
},
{
"id_field": "acronym",
"id_value": [
"Protocol AF"
]
}
] | https://clinicaltrials.gov/study/NCT04661358 | Fenofibrate for Prevention of DR Worsening | This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline.<br/>In addition to evaluating efficacy, this study aims to ... | A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening | [
{
"description": "Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.",
"name": "Fenofibrate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_title": "Fenofibrate 160-mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR v... | [
"Diabetic Retinopathy"
] | [
"Jaeb Center For Health Research Foundation, Inc."
] | [
"The Leona M. & Harry B. Helmsley Charitable Trust",
"Juvenile Diabetes Research Foundation",
"Roche Pharma AG",
"National Institutes of Health",
"National Eye Institute"
] | [
[
{
"name": "非诺贝特",
"lang": "CN"
},
{
"name": "Fenofibrate",
"lang": "EN"
},
{
"name": "フェノフィブラート",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Protocol AF"
}
] |
NCT00085826 | [
{
"id_field": "org_study_id",
"id_value": [
"028"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00021411",
"NCT00036322"
]
}
] | https://clinicaltrials.gov/study/NCT00085826 | A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients | Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged survival when compared to T... | A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) Versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy | [
{
"name": "Exisulind",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Non-Small Cell Lung Cancer"
] | [
"Astellas Pharma, Inc."
] | [
"OSI Pharmaceuticals, Inc."
] | [
[
{
"name": "依昔舒林",
"lang": "CN"
},
{
"name": "Exisulind",
"lang": "EN"
}
]
] | null |
NCT04185012 | [
{
"id_field": "org_study_id",
"id_value": [
"NAPPREB"
]
},
{
"id_field": "acronym",
"id_value": [
"NAPPREB"
]
}
] | https://clinicaltrials.gov/study/NCT04185012 | NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab | Background and rationale:<br/>Phase III-b study.<br/>Population and patient selection criteria: Adult patients with Chronic Rhinosinusitis with Nasal Polyps (allergic and non-allergic) requiring at least 1000 mg oral prednisone over the previous twelve months to control symptoms of rhinosinusitis, and with:<br/>* Nasal... | NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab | [
{
"description": "Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period",
"name": "Benralizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Placebo administered subcutaneou... | [
{
"design_group_description": "Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks",
"design_group_title": "Benralizumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35... | [
"Nasal Polyps"
] | [
"Humanitas Research Hospital"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "本瑞利珠单抗",
"lang": "CN"
},
{
"name": "Benralizumab",
"lang": "EN"
},
{
"name": "ベンラリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NAPPREB"
}
] |
NCT00984750 | [
{
"id_field": "org_study_id",
"id_value": [
"DIABASI"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2007-005925-31"
]
},
{
"id_field": "acronym",
"id_value": [
"DIABASI"
]
}
] | https://clinicaltrials.gov/study/NCT00984750 | Acetyl-L-Carnitine in Type 2 Diabetes | Decreased insulin sensitivity (or insulin resistance) is a major risk factor for type 2 diabetes mellitus and renal and cardiovascular disease. It is the key component and, possibly, a pathogenetic factor of the metabolic syndrome - a clustering of arterial hypertension, obesity, impaired glucose tolerance, dyslipidemi... | A Prospective, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effect of 6-month Acetylcarnitine Therapy on Arterial Blood Pressure, Lipid and Metabolic Profile, and Kidney Function in Hypertensive Patients With Type 2 Diabetes on Background Simvastatin Therapy | [
{
"description": "acetyl-L-carnitine: 4 tablets of 500 mg a day<br/>simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability",
"name": "acetyl-L-carnitine/statin (simvastatin)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"des... | [
{
"design_group_description": "Statin and acetyl-L-carnitine",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "acetyl-L-carnitine: 4 tablets of 50... | [
"Diabetes Type 2",
"Hypertension"
] | [
"Istituto di Ricerche Farmacologiche Mario Negri"
] | [
"Leadiant Biosciences, Inc."
] | [
[
{
"name": "辛伐他汀",
"lang": "CN"
},
{
"name": "Simvastatin",
"lang": "EN"
},
{
"name": "シンバスタチン",
"lang": "JP"
}
],
[
{
"name": "乙酰左旋肉碱",
"lang": "CN"
},
{
"name": "Acetyl-L-carnitine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DIABASI"
}
] |
NCT00697697 | [
{
"id_field": "org_study_id",
"id_value": [
"MAP0010-CL-P301X"
]
}
] | https://clinicaltrials.gov/study/NCT00697697 | A Study of 2 Doses of MAP0010 in Asthmatic Children | The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period. | A Randomized, Double-blind, Active-controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study) | [
{
"description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks",
"name": "0.135mg MAP0010",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "0.25mg MAP0010 (unit dose budesonide) delivered by nebulization ... | [
{
"design_group_description": "0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks",
"design_group_title": "0.135mg MAP0010",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Asthma"
] | [
"Allergan UC"
] | [
"MAP Pharmaceuticals LLC"
] | [
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
]
] | null |
NCT00529620 | [
{
"id_field": "org_study_id",
"id_value": [
"5184"
]
}
] | https://clinicaltrials.gov/study/NCT00529620 | Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal | The purpose of this trial is to compare the acceptability, efficacy and safety of three alternative drug regimens for use for seasonal Intermittent Preventive Treatment to prevent malaria in children. Children aged 2 months to 5 years will be randomized to receive IPT with one of three regimens during the transmission ... | Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal | [
{
"description": "Monthly treatments during the malaria transmission season",
"name": "sulfalene-pyrimethamine plus amodiaquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Dualkin"
],
"type": "Drug"
},
{
"description": "Monthly treatments during th... | [
{
"design_group_description": "sulfalene pyrimethamine plus amodiaquine",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Monthly treatments ... | [
"Malaria"
] | [
"London School of Hygiene & Tropical Medicine"
] | [
"Cheikh Anta Diop University"
] | [
[
{
"name": "磺胺林",
"lang": "CN"
},
{
"name": "Sulfalene",
"lang": "EN"
}
],
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
],
[
{
"name": "磺胺多辛乙胺嘧啶",
"lang... | null |
NCT01933919 | [
{
"id_field": "org_study_id",
"id_value": [
"M13-970"
]
}
] | https://clinicaltrials.gov/study/NCT01933919 | A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder | The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participant... | A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder | [
{
"description": "Film-coated tablet containing 25 mg of fluvoxamine maleate",
"name": "Fluvoxamine maleate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Depromel",
"Luvox",
"SME3110"
],
"type": "Drug"
},
{
"description": "Placebo tablet ... | [
{
"design_group_description": "In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximu... | [
"Obsessive Compulsive Disorder"
] | [
"AbbVie, Inc."
] | [
"Meiji Seika Pharma Co., Ltd."
] | [
[
{
"name": "马来酸氟伏沙明",
"lang": "CN"
},
{
"name": "Fluvoxamine Maleate",
"lang": "EN"
},
{
"name": "フルボキサミンマレイン酸塩",
"lang": "JP"
}
]
] | null |
NCT07112144 | [
{
"id_field": "org_study_id",
"id_value": [
"B1004-F20240930-3"
]
}
] | https://clinicaltrials.gov/study/NCT07112144 | Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial | The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months. | Phase III Clinical Trials to Evaluate the Immunogenicity and Safety of Adsorption-free Diphtheria and Tetanus (Three-component) Combined Vaccine in 2-month-old Infants and Young Children | [
{
"description": "Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml；Injection；",
"name": "DTacP",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Vaccinate 1 d... | [
{
"design_group_title": "DTacP",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, ... | [
"Prevent Whooping Cough",
"Prevent Diphtheria",
"Prevent Tetanus"
] | [
"Changchun BCHT Biotechnology Co."
] | [
"Shandong Province Centers for Disease Control and Prevention"
] | [
[
{
"name": "吸附无细胞百白破(三组分)联合疫苗(长春百克生物)",
"lang": "CN"
},
{
"name": "Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed(Changchun BCHT Biotechnology Co.)",
"lang": "EN"
}
]
] | null |
NCT00683514 | [
{
"id_field": "org_study_id",
"id_value": [
"PM 0259 CA 304 J1"
]
}
] | https://clinicaltrials.gov/study/NCT00683514 | Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer | This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral vinorelbine and cisplatin plus Best Supportive Care (BSC) or BSC alone in patients with unre... | Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study | [
{
"description": "q 28 days :<br/>* 50 mg/m2 oral vinorelbine d1, d8, d15<br/>* 20 mg/m2/d cisplatin from d1 to d4",
"name": "Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"descript... | [
{
"design_group_description": "* cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy<br/>* cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and ci... | [
"NSCLC"
] | [
"Pierre Fabre Medicament Information"
] | [
"Pierre Fabre Pharma GmbH"
] | [
[
{
"name": "长春瑞滨双酒石酸盐",
"lang": "CN"
},
{
"name": "Vinorelbine Tartrate",
"lang": "EN"
},
{
"name": "ビノレルビン酒石酸塩",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
... | null |
NCT01483560 | [
{
"id_field": "org_study_id",
"id_value": [
"GN10DI406"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-000300-18"
]
},
{
"id_field": "acronym",
"id_value": [
"REMOVAL"
]
}
] | https://clinicaltrials.gov/study/NCT01483560 | REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) | The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (... | Phase 3 Study of Metformin in Adults With Type 1 Diabetes | [
{
"description": "3 years treatment duration",
"name": "Metformin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Glucophage"
],
"type": "Drug"
},
{
"description": "3 years duration",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily",
"design_group_title": "Metformin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{... | [
"Diabetes Mellitus, Type 1"
] | [
"University of Glasgow"
] | [
"University Of Dundee",
"Merck Serono SA",
"NHS Greater Glasgow & Clyde",
"Maastricht UMC+",
"University of Western Ontario",
"Juvenile Diabetes Research Foundation",
"University of Wisconsin-Madison",
"Steno Diabetes Center A/S",
"University of Melbourne",
"Imperial College London",
"Itamar Med... | [
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
"name": "メトホルミン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "48ae2558e2808d853ee5ad5498d3e283",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "89d228e598a2e8d82a8dae52ee022322",
"s... |
NCT03283059 | [
{
"id_field": "org_study_id",
"id_value": [
"OHAAS-III"
]
}
] | https://clinicaltrials.gov/study/NCT03283059 | Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease | Inhibition of acetylcholinesterase has been a effective treatment for Alzheimer's disease. Octohydroaminoacridine, a new acetylcholinesterase inhibitor, is a potential treatment for Alzheimer's disease. The investigators conducted a 26 weeks, randomized, double-blind, double-dummy, placebo- and positive- parallel contr... | Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study | [
{
"description": "Octohydroaminoacridine Succinate Tablet:4mg P.O. tid",
"name": "Octohydroaminoacridine Succinate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Aricept 5mg/day, P.O.",
"name": "Aricept",
"normalized_type": "3d1aa88261d64... | [
{
"design_group_description": "Octohydroaminoacridine Succinate Tablet 4mg P.O. tid",
"design_group_title": "Octohydroaminoacridine Succinate Tablet",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"in... | [
"Alzheimer Disease"
] | [
"Shanghai Mental Health Center"
] | [
"Hygk",
"Jiangsu Sheneryang High-Tech Co., Ltd."
] | [
[
{
"name": "琥珀八氢氨吖啶",
"lang": "CN"
},
{
"name": "Octahydroaminoacridine succinate",
"lang": "EN"
}
]
] | null |
NCT03888066 | [
{
"id_field": "org_study_id",
"id_value": [
"PAT-CR-302"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-005030-38"
]
},
{
"id_field": "acronym",
"id_value": [
"DIAMOND"
]
}
] | https://clinicaltrials.gov/study/NCT03888066 | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) | The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients. | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND) | [
{
"description": "The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be d... | [
{
"design_group_description": "Subjects will be randomized to receive a daily dose of patiromer with possible dose adjustments based on subsequent local serum potassium levels.",
"design_group_title": "Group 1: Patiromer",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b... | [
"Hyperkalemia"
] | [
"Corden Pharma Fribourg SA"
] | [
"Syneos Health, Inc."
] | [
[
{
"name": "帕替罗姆",
"lang": "CN"
},
{
"name": "Patiromer sorbitex calcium",
"lang": "EN"
},
{
"name": "パチロマーソルビテクスカルシウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "233ea584ea88a528899928a48032a888",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "2e22559e8d5e99a8828203e93223e49a",
"s... |
NCT06628778 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00469377 - CRITICAL-Kids-TP"
]
},
{
"id_field": "acronym",
"id_value": [
"CRITICALKidsTP"
]
}
] | https://clinicaltrials.gov/study/NCT06628778 | Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP) | Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States de... | Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP) | [
{
"description": "Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge",
"name": "Dalteparin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "This arm will receive the study intervention, dalteparin thromboprophylaxis during pediatric intensive care unit hospitalization",
"design_group_title": "Dalteparin Thromboprophylaxis",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b556156... | [
"Venous Thromboembolism (VTE)"
] | [
"Johns Hopkins All Children's Hospital"
] | [
"University of California San Diego"
] | [
[
{
"name": "达肝素钠",
"lang": "CN"
},
{
"name": "Dalteparin Sodium",
"lang": "EN"
},
{
"name": "ダルテパリンナトリウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CRITICALKidsTP"
}
] |
NCT02304523 | [
{
"id_field": "org_study_id",
"id_value": [
"CTC-BCS-CDFR0612/0613_3"
]
}
] | https://clinicaltrials.gov/study/NCT02304523 | Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy | The purpose of this study is to evaluate the safety and efficacy of CDFR0612 and CDFR0613 compared to PEG+picosulfate (Coolprep Powder) preparation. The effectiveness for bowel cleansing will be assessed with Harefield Cleansing Scale (HCS) by blinded assessor. | A Prospective, Randomized, Single-blinded (Evaluator), 3-treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of CDFR0612 and CDFR0613 | [
{
"description": "Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.",
"name": "CDFR0612",
"normalized_type": "3d1aa88261d64c038... | [
{
"design_group_description": "CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.<br/>These processes will be in evening at one day before colonoscopy and in early morning ... | [
"Colonoscopy Preparation",
"Colon Disease"
] | [
"CTC Bio, Inc."
] | [
"Symyoo"
] | [
[
{
"name": "CDFR0612",
"lang": "EN"
}
],
[
{
"name": "CDFR0613",
"lang": "EN"
}
]
] | null |
NCT01905592 | [
{
"id_field": "org_study_id",
"id_value": [
"213551"
]
},
{
"id_domain": "EORTC, BIG",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"1307-BCG, BIG5-13"
]
},
{
"id_domain": "Tesaro",
"id_field": "secondary_id",
"id_type": "Ot... | https://clinicaltrials.gov/study/NCT01905592 | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice | A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | [
{
"description": "300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops",
"name": "niraparib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"formerly MK-4827"
],
"type": "Drug"
},
{
"description": "Choice of 4 standa... | [
{
"design_group_description": "Physician may select from 4 active comparators",
"design_group_title": "Physician's choice",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description... | [
"Neoplasms, Breast",
"Carcinoma of Breast",
"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
"BRCA1 Gene Mutation",
"BRCA2 Gene Mutation",
"Ovarian Neoplasms"
] | [
"Tesaro, Inc."
] | [
"Myriad Genetic Laboratories, Inc.",
"Breast International Group",
"European Organisation for Research & Treatment of Cancer",
"US Oncology Research LLC",
"Sarah Cannon Research Institute LLC"
] | [
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
},
{
"name": "ニラパリブトシル酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e8e920d2ea220220adaa0423ed83295",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e08a584883aae85a0594da20a2233925",
"s... |
NCT00910780 | [
{
"id_field": "org_study_id",
"id_value": [
"08-0858"
]
},
{
"id_field": "acronym",
"id_value": [
"SMEAC"
]
}
] | https://clinicaltrials.gov/study/NCT00910780 | Metabolic Effects of Antipsychotic Substitution in Children | This project aims to identify whether therapeutic substitution of aripiprazole for risperidone or olanzapine, combined with standard nutrition intervention, will impact the metabolic changes associated with antipsychotic treatment in children and adolescents. | Metabolic Effects of Antipsychotic Substitution in Children | [
{
"description": "via oral tablets, everyday",
"name": "Aripiprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "via oral tablets, taken once daily",
"name": "Zyprexa",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_title": "Staying on Risperdal",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "via oral tablets, taken once daily",
"intervention_name": "Risperdal... | [
"Diabetes"
] | [
"Washington University School of Medicine"
] | [
"Pfizer Inc."
] | [
[
{
"name": "阿立哌唑",
"lang": "CN"
},
{
"name": "Aripiprazole",
"lang": "EN"
},
{
"name": "アリピプラゾール水和物",
"lang": "JP"
}
],
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"na... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SMEAC"
}
] |
NCT01848873 | [
{
"id_field": "org_study_id",
"id_value": [
"AUSA-amlodipine"
]
}
] | https://clinicaltrials.gov/study/NCT01848873 | Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine | To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein. | Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension and Hyperhomocysteinemia ：a Double-blind Randomized Controlled Trial | [
{
"description": "amlodipine 5mg daily",
"name": "Amlodipine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"control"
],
"type": "Drug"
},
{
"description": "5mg amlodipine combined with 0.4 mg of folic acid, daily.",
"name": "amlodipine-FA tablet, ... | [
{
"design_group_description": "5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.",
"design_group_title": "amlodipine-FA tablet, low dose group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention"... | [
"Essential Hypertension"
] | [
"Shenzhen Ausa Pharmed Co. Ltd."
] | [
"The First Hospital of Harbin Medical University",
"Chinese People's Liberation Army General Hospital",
"Ruijin Hospital",
"Guangdong General Hospital",
"Huazhong University of Science & Technology",
"Capital University of Medical Sciences",
"The Second Affiliated Hospital Zhejiang University",
"Xi'an... | [
[
{
"name": "苯磺酸氨氯地平",
"lang": "CN"
},
{
"name": "Amlodipine Besylate",
"lang": "EN"
},
{
"name": "アムロジピンベシル酸塩",
"lang": "JP"
}
]
] | null |
NCT00389168 | [
{
"id_field": "org_study_id",
"id_value": [
"CV131-052"
]
},
{
"id_field": "acronym",
"id_value": [
"SILVHIA"
]
}
] | https://clinicaltrials.gov/study/NCT00389168 | Irbesartan and Atenolol in Hypertensive Heart Disease | The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure.<br/>This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and... | Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy | [
{
"description": "Titrated to 300 mg od, 48 weeks.",
"name": "Irbesartan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aprovel"
],
"type": "Drug"
},
{
"description": "Titrated to 100 mg od, 48 weeks.",
"name": "Atenolol",
"normalized_type": "... | [
{
"design_group_description": "Irbesartan per os titrated to 300 mg od, 48 weeks",
"design_group_title": "Irbesartan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Titrat... | [
"Hypertension"
] | [
"Karolinska Institutet"
] | [
"Sanofi",
"Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt",
"Bristol Myers Squibb Co."
] | [
[
{
"name": "厄贝沙坦",
"lang": "CN"
},
{
"name": "Irbesartan",
"lang": "EN"
},
{
"name": "イルベサルタン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2a5e3e52ae2d05a0d2d82ed9e2e935e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "2e5882e38a2ea532a2de222a28985e29",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT00989339 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00019153"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IRB00019153"
]
}
] | https://clinicaltrials.gov/study/NCT00989339 | Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers | Recent evidence suggests that increased levels of a circulation fat (free fatty acids or FFAs) can cause high blood pressure and cardiac complications. Intralipid is the only type of fat approved by the FDA for clinical use. It is usually used as nutrition support in malnourished patients. The investigators' preliminar... | Effects of Intralipid and Olive Oil Infusion on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function, Autonomic Nervous System, Insulin Sensitivity and Carbohydrate Metabolism | [
{
"description": "Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.",
"name": "Twenty-four Hour TPN and Saline Infusion",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 m... | [
"Diabetes",
"Hypertension",
"Obesity"
] | [
"Emory University"
] | [
"American Diabetes Association"
] | [
[
{
"name": "奥普瑞白介素",
"lang": "CN"
},
{
"name": "Oprelvekin",
"lang": "EN"
}
]
] | null |
NCT07544056 | [
{
"id_field": "org_study_id",
"id_value": [
"GBMT-209B-P02"
]
}
] | https://clinicaltrials.gov/study/NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (T... | A Randomized, Controlled, Open-label, Multi-center, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer | [
{
"description": "Dosage: 150 mg orally per dose. Schedule: Administered on Day 1 (D1; before dinner), Day 2 (D2; before breakfast), Day 8 (D8; before dinner), and Day 9 (D9; before breakfast) of each 21-day cycle.<br/>Timing: On chemotherapy days (D2 and D9), BEBT-209 must be taken at least 30 minutes before b... | [
{
"design_group_description": "Participants in this arm will receive carboplatin (2 [mg/mL/min] × [CrCl (mL/min) + 25]) and gemcitabine (1000 mg/m²) in 21-day cycles. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.",
"design_group_title": "Carboplatin plus Gem... | [
"Locally Advanced Triple-negative Breast Cancer",
"Metastatic Triple-negative Breast Cancer"
] | [
"BeBetter Med, Inc."
] | [
"Hunan Cancer Hospital",
"Sun Yat-Sen Memorial Hospital"
] | [
[
{
"name": "BEBT-209",
"lang": "EN"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"n... | null |
NCT03530085 | [
{
"id_field": "org_study_id",
"id_value": [
"Dec+FB-Elderly AML-2018"
]
}
] | https://clinicaltrials.gov/study/NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (AML) in complete remission (CR). At present, the best conditioning regimen for elderly AML in CR remains in discussion. In this prospective study, the safety and efficacy of ... | Decitabine+ Fludarabine+Busulfan Conditioning Regimen for Elderly Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | [
{
"description": "Decitabine was administered at 20mg/m2/day on days -9 to -7.",
"name": "Decitabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.",
"name": "Busulfan (BU)",
"n... | [
{
"design_group_description": "For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -9 to -7；Fludarabine(Flu) 30mg/m2/day on days -6 to -3；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).",
"design_group_title": "Dec+Flu+Bu ... | [
"Acute Myeloid Leukemia",
"Allogeneic Hematopoietic Stem Cell Transplantation",
"Conditioning",
"Elderly"
] | [
"Nanfang Hospital"
] | [
"Guangzhou First People's Hospital",
null,
"Peking University People's Hospital",
"Sun Yat-Sen Memorial Hospital",
"The Third Affiliated Hospital, Sun Yat-Sen University"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{... | null |
NCT03500848 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-GDEK-001"
]
}
] | https://clinicaltrials.gov/study/NCT03500848 | Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation | This is a multicenter, open-label, randomized, controlled clinical trial, in order to compare sirolimus-based (tacrolimus-free) versus tacrolimus-based (sirolimus-free) immunosuppression regimen for Hepatocellular Carcinoma (HCC) patients after liver transplantation. | Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation: A Multicenter, Open-label, Randomized, Controlled Clinical Trial in Liver Transplant Recipients With Hepatocellular Carcinoma | [
{
"description": "Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough l... | [
{
"design_group_description": "Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids",
"design_group_title": "Tacrolimus-based group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Liver Transplantation"
] | [
"Southern Medical University"
] | [
"the First Affiliated Hospital of Sun Yat-Sen University",
"Nanfang Hospital"
] | [
[
{
"name": "他克莫司",
"lang": "CN"
},
{
"name": "Tacrolimus",
"lang": "EN"
},
{
"name": "タクロリムス水和物",
"lang": "JP"
}
],
[
{
"name": "西罗莫司",
"lang": "CN"
},
{
"name": "Sirolimus",
"lang": "EN"
},
{
"name": ... | null |
NCT06696248 | [
{
"id_field": "org_study_id",
"id_value": [
"CZXH-PH-ALV-2403"
]
}
] | https://clinicaltrials.gov/study/NCT06696248 | Carvedilol and Alverine in Portal Hypertension | Brief summaries of CZXH-PH-ALV-2403 The goal of this clinical trial is to learn if the combination of alverine and carvedilol works to treat portal hypertension in adult patients with liver cirrhosis. It will also learn about the safety of alverine.<br/>The main question it aims to answer is:<br/>For patients with live... | The Efficacy of Carvedilol Combined with Compound Alverine Citrate Soft Capsules in the Treatment of Portal Hypertension in Patients with Liver Cirrhosis: a Prospective, Open-label, Multicentre, Randomised Controlled Trial | [
{
"description": "On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simet... | [
{
"design_group_description": "On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60... | [
"Hypertension, Portal"
] | [
"Shanghai Changzheng Hospital"
] | [
"Shanghai East Hospital"
] | [
[
{
"name": "枸橼酸阿尔维林",
"lang": "CN"
},
{
"name": "Alverine Citrate",
"lang": "EN"
}
],
[
{
"name": "卡维地洛",
"lang": "CN"
},
{
"name": "Carvedilol",
"lang": "EN"
},
{
"name": "カルベジロール",
"lang": "JP"
}
]
] | null |
NCT03040726 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-0843"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2017-00599"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03040726 | Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer | This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting. | Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients | [
{
"description": "Given PO",
"name": "Netupitant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CID6451149",
"D05152",
"RO 67-3189/000"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "Palonosetron",
"normalized_type": "3... | [
{
"design_group_description": "Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Group I (netupitant, palonosetron hydrochloride)",
"design_group_type": "Experimental",
... | [
"Malignant Neoplasm",
"Nausea",
"Vomiting"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute",
"Helsinn Healthcare SA"
] | [
[
{
"name": "奈妥吡坦",
"lang": "CN"
},
{
"name": "Netupitant",
"lang": "EN"
}
],
[
{
"name": "盐酸帕洛诺司琼",
"lang": "CN"
},
{
"name": "Palonosetron hydrochloride",
"lang": "EN"
},
{
"name": "パロノセトロン塩酸塩",
"lang": "JP"
}
... | null |
NCT00002930 | [
{
"id_field": "org_study_id",
"id_value": [
"96-079"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA008748"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MSKCC-96079"
]
},
{
"id_field": "secon... | https://clinicaltrials.gov/study/NCT00002930 | PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery | RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.<br/>PURPOSE: Phase II/III trial to study the effectiveness of fludeoxyglucose F 18 PET scans in measuring response to induction chemothe... | Whole-Body 18F-Fluorodeoxyglucose Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas | [
{
"name": "positron emission tomography",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"name": "fludeoxyglucose F 18",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"single_or_multi": "single_drug",
"type": "Radiation"
}
] | null | [
"Esophageal Cancer",
"Lung Cancer"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "氟[18F]脱氧葡糖",
"lang": "CN"
},
{
"name": "Fludeoxyglucose F-18",
"lang": "EN"
},
{
"name": "フルデオキシグルコース(18F)",
"lang": "JP"
}
]
] | null |
NCT03979976 | [
{
"id_field": "org_study_id",
"id_value": [
"Ramipril.unifesp"
]
}
] | https://clinicaltrials.gov/study/NCT03979976 | Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus | The aim of this study was to evaluate the effect of ramipril on the endothelial function and on the number of endothelial progenitor cells (EPCs) in systemic lupus erythematosus (SLE) patients. | Ramipril Improves Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus: a Randomized and Controlled Study. | [
{
"description": "Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence",
"name": "Ramipril",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"angiotensin-converting enzyme ... | [
{
"design_group_description": "Use of ramipril 10mg/day per 12 weeks",
"design_group_title": "ramipril group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Use of ra... | [
"Systemic Lupus Erythematosus"
] | [
"Universidade Federal De Sao Paulo"
] | [
"Fundação de Amparo à Pesquisa do Estado de São Paulo"
] | [
[
{
"name": "雷米普利",
"lang": "CN"
},
{
"name": "Ramipril",
"lang": "EN"
}
]
] | null |
NCT04137107 | [
{
"id_field": "org_study_id",
"id_value": [
"A221805"
]
},
{
"id_domain": "NCI Clinical Trial Reporting Program",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-04727"
]
}
] | https://clinicaltrials.gov/study/NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve d... | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study | [
{
"description": "Given standard of care oxaliplatin",
"name": "Oxaliplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Given PO",
"name": "Duloxetine Hydrochloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "... | [
{
"design_group_description": "Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 3... | [
"Stage II Colorectal Cancer AJCC v8",
"Stage III Colorectal Cancer AJCC v8"
] | [
"Alliance Foundation Trials LLC"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸度洛西汀",
"lang": "CN"
},
{
"name": "Duloxetine Hydrochloride",
"lang": "EN"
},
{
"name": "デュロキセチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"code": "e32d8a2a0e292ee33825ead38d054258",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Alliance A221805"
}
] |
NCT07262723 | [
{
"id_field": "org_study_id",
"id_value": [
"59.127.1557.013.19.PG.2025.364"
]
}
] | https://clinicaltrials.gov/study/NCT07262723 | Levosimendan in Acute Decompensated Heart Failure | Acute decompensated heart failure (ADHF) is one of the major causes of hospitalization and mortality worldwide. Despite advances in medical treatments, managing ADHF remains complex, especially in high-risk populations. Levosimendan, a calcium sensitizer that improves myocardial contractility and reduces complications ... | Efficacy and Safety of Levosimendan in Patients With Acute Decompensated Heart Failure: A Real-World Evidence | [
{
"description": "Levosimendan is a calcium-sensitizing inotrope with vasodilatory effects, enhancing heart contractility without raising oxygen demand and promoting vascular relaxation. In this trial, patients will be randomized to receive either standard care alone or standard care plus levosimendan (0.1 μg/k... | [
{
"design_group_description": "Participants will receive standard guideline-directed care for heart failure plus levosimendan infusion. Levosimendan will be administered as a continuous intravenous infusion at 0.1 μg/kg/min for 24 hours, in addition to standard therapy.",
"design_group_title": "Intervention... | [
"Acute Decompensated Heart Failure (ADHF)"
] | [
"Chittagong Medical College"
] | [
"Beacon Pharmaceuticals Plc"
] | [
[
{
"name": "左西孟旦",
"lang": "CN"
},
{
"name": "Levosimendan",
"lang": "EN"
}
]
] | null |
NCT00430001 | [
{
"id_field": "org_study_id",
"id_value": [
"HERNATA"
]
}
] | https://clinicaltrials.gov/study/NCT00430001 | Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer | In an open-label randomised phase III-trial patients with metastatic HER2-positive breast cancer naive to chemotherapy with normal organ function and WHO performance status < 3 are randomised to receive either docetaxel 100 mg/m2 i.v. plus trastuzumab 6 mg/kg (8 mg/kg loading dose) q 3 weeks or vinorelbine 30 or 35 mg/... | A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer | [
{
"name": "docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "vinorelbine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": ... | null | [
"Breast Cancer"
] | [
"Danish Breast Cancer Cooperative Group"
] | [
"Hoffmann-La Roche, Inc.",
"Sanofi"
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "长春瑞滨双酒石酸盐",
"lang": "CN"
},
{
"name": "Vinorelbine Tartrate",
"lang": "EN"
... | null |
NCT00213083 | [
{
"id_field": "org_study_id",
"id_value": [
"Population Council #322"
]
}
] | https://clinicaltrials.gov/study/NCT00213083 | Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission | The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use. | Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women | [
{
"name": "Carraguard (PC-515)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"HIV Infections",
"AIDS",
"Sexually Transmitted Diseases",
"HIV Seroconversion"
] | [
"The Population Council, Inc."
] | [
"Gates Foundation (United States)"
] | [
[
{
"name": "PC-515",
"lang": "EN"
}
]
] | null |
NCT00690573 | [
{
"id_field": "org_study_id",
"id_value": [
"M10-240"
]
}
] | https://clinicaltrials.gov/study/NCT00690573 | Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis | To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis | A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis | [
{
"description": "Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).",
"name": "Adalimumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"ot... | [
{
"design_group_title": "Adalimumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Adalimumab administered subcutaneously every other week, with dosage determined by body wei... | [
"Juvenile Rheumatoid Arthritis"
] | [
"Abbott Laboratories"
] | [
"Eisai Co., Ltd."
] | [
[
{
"name": "阿达木单抗",
"lang": "CN"
},
{
"name": "Adalimumab",
"lang": "EN"
},
{
"name": "アダリムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00116220 | [
{
"id_field": "org_study_id",
"id_value": [
"95-096"
]
}
] | https://clinicaltrials.gov/study/NCT00116220 | Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer | This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival. | A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer | [
{
"description": "Androgen suppression therapy",
"name": "Flutamide (Eulexin) and Lupron or Zoladex",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Once a day, 4-5 days per week for approximately 2 months",
"name": "External Beam Radiotherapy"... | [
{
"design_group_description": "External beam radiation therapy + 6 months total androgen ablation",
"design_group_title": "Treatment 1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interventio... | [
"Prostate Cancer"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"The Brigham & Women's Hospital, Inc.",
"Beth Israel Deaconess Medical Center, Inc.",
"West Metro Medical Center"
] | [
[
{
"name": "唑来膦酸",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ゾレドロン酸水和物",
"lang": "JP"
}
],
[
{
"name": "氟他胺",
"lang": "CN"
},
{
"name": "Flutamide",
"lang": "EN"
},
{
"nam... | null |
NCT05345639 | [
{
"id_field": "org_study_id",
"id_value": [
"49RC21_0251"
]
},
{
"id_field": "acronym",
"id_value": [
"PABLOS"
]
}
] | https://clinicaltrials.gov/study/NCT05345639 | Chest Wall Block After Sternotomy: Randomized Controlled Trial in Cardiac Surgery: (PABLOS Study) | The main objective is to compare the effectiveness of LocoRegional Anesthesia (LRA) (bilateral transverse thoracic block or bilateral parasternal block) in addition to standard management compared to standard management alone (general anesthesia without LRA) on the FQoR-15 (French Quality of Recovery - 15 score) at H+2... | Chest Wall Block After Sternotomy: Randomized Controlled Trial in Cardiac Surgery: (PABLOS Study) | [
{
"description": "Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, at the end of surgery in the operating room. Once in the desired plane depending on the randomisation (transverse or parasternal), a volume of 20 ml of ropivacaine at 2 mg/ml is injected on each side of t... | [
{
"design_group_description": "At the end of the surgery, realisation of a bilateral transverse thoracic block. (20ml of Naropeine 0.2%, each side) Followed by standard analgesic treatment.",
"design_group_title": "TTP group (= Transversus Thoracic Plane block = Deep PIP = Deep parasternal intercostal plane... | [
"Pain, Postoperative",
"Cardiac Surgery"
] | [
"Centre Hospitalier Universitaire d'Angers"
] | [
"Fondation APICIL"
] | [
[
{
"name": "盐酸罗哌卡因",
"lang": "CN"
},
{
"name": "Ropivacaine Hydrochloride",
"lang": "EN"
},
{
"name": "ロピバカイン塩酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PABLOS"
}
] |
NCT04695860 | [
{
"id_field": "org_study_id",
"id_value": [
"BUR03"
]
},
{
"id_field": "acronym",
"id_value": [
"BurGER"
]
}
] | https://clinicaltrials.gov/study/NCT04695860 | Anti-FGF23 (Burosumab) in Adult Patients With XLH | X-linked hypophosphatemia (XLH) rare genetic disorder due by inactivating mutations in the PHEX gene leading to increased levels in FGF-23. Elevated FGF-23 reduces renal phosphate reabsorbtion and and limits 1-alpha hydroxylase driven Vitamin D activation, eventually leading to phosphate wasting, defective bone mineral... | An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER | [
{
"description": "Q4w, 1mg/kg Body weight, s.c.",
"name": "Burosumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Burosumab Q4W, 1mg/kg body weight s.c.",
"design_group_title": "Open label Burosumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Q4w, 1m... | [
"X-linked Hypophosphatemia"
] | [
"Universitätsklinikum Würzburg"
] | [
"Kyowa Kirin, Inc."
] | [
[
{
"name": "布罗索尤单抗",
"lang": "CN"
},
{
"name": "Burosumab-TWZA",
"lang": "EN"
},
{
"name": "ブロスマブ （遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BurGER"
}
] |
NCT03141073 | [
{
"id_field": "org_study_id",
"id_value": [
"HMM0302"
]
}
] | https://clinicaltrials.gov/study/NCT03141073 | Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects | This study evaluates the efficacy and safety and population PK of HMS5552 add-on to Metformin in adult type 2 diabetic subjects. There will be 2 groups in the first 24 weeks, one group will receive HMS5552 plus Metformin, while the other group will receive placebo plus Metformin; after 24 weeks, all subjects will recei... | A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 add-on to Metformin With Additional 28-week Open-label Treatment to Evaluate the Safety in T2DM Subjects | [
{
"description": "BID oral administration",
"name": "HMS5552",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Glucokinase Activator (GKA)"
],
"type": "Drug"
},
{
"description": "BID oral administration",
"name": "Placebo",
"normalized_type": "3d... | [
{
"design_group_description": "75mg BID",
"design_group_title": "HMS5552",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "BID oral administration",
"intervention_na... | [
"Diabetes Mellitus, Type 2"
] | [
"Hua Medicine (Shanghai) Co., Ltd."
] | [
"Labcorp Drug Development, Inc."
] | [
[
{
"name": "多格列艾汀",
"lang": "CN"
},
{
"name": "Dorzagliatin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "42a85523daaa0e32da8e2229e85ea285",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "5a22e8282e3e54d5e85ead848e22a22a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DAW... |
NCT02449070 | [
{
"id_field": "org_study_id",
"id_value": [
"D-1407-011-030"
]
}
] | https://clinicaltrials.gov/study/NCT02449070 | Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction | The purpose of this study is to determine whether nicorandil reduce cardiac infarct size in patient with ST-segment elevation acute myocardial infarction. | Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction : A Randomized Clinical Trial | [
{
"description": "4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting",
"name": "Nicorandil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Nicrodandil"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.",
"design_group_title": "Nicorandil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Myocardial Infarction"
] | [
"Pusan National University Hospital"
] | [
"JW PHARMACEUTICAL Corp."
] | [
[
{
"name": "尼可地尔",
"lang": "CN"
},
{
"name": "Nicorandil",
"lang": "EN"
},
{
"name": "ニコランジル",
"lang": "JP"
}
]
] | null |
NCT04516057 | [
{
"id_field": "org_study_id",
"id_value": [
"1968"
]
},
{
"id_field": "acronym",
"id_value": [
"NAB-IT"
]
},
{
"id_field": "secondary_id",
"id_value": [
"1968"
]
}
] | https://clinicaltrials.gov/study/NCT04516057 | Nabilone for Agitation Blinded Intervention Trial | This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increase... | Nabilone for Agitation Blinded Intervention Trial | [
{
"description": "After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.",
"name": "Nabilone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other... | [
{
"design_group_description": "Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.",
"design_group_title": "Nabilone Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Alzheimer Disease",
"Agitation"
] | [
"Sunnybrook Health Sciences Centre"
] | [
"Alzheimers Drug Discovery Foundation"
] | [
[
{
"name": "大麻隆",
"lang": "CN"
},
{
"name": "Nabilone",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NAB-IT"
}
] |
NCT03791918 | [
{
"id_field": "org_study_id",
"id_value": [
"HCC-S065"
]
}
] | https://clinicaltrials.gov/study/NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria | Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody Versus Transarterial Chemoembolization for Intermediate-stage Hepatocellular Carcinoma Beyond Up-to-seven Criteria | [
{
"description": "12 mg (or 8 mg) once daily (QD) oral dosing.",
"name": "Lenvatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"E7080, Lenvima"
],
"type": "Drug"
},
{
"description": "3mg/kg intravenously every 2 weeks",
"name": "PD-1 antibody"... | [
{
"design_group_description": "Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment ... | [
"Hepatocellular Carcinoma"
] | [
"Sun Yat-Sen University"
] | [
"KaiPing Central Hospital",
"Guangzhou No. 12 People's Hospital"
] | [
[
{
"name": "甲磺酸仑伐替尼",
"lang": "CN"
},
{
"name": "Lenvatinib mesylate",
"lang": "EN"
},
{
"name": "レンバチニブメシル酸塩",
"lang": "JP"
}
]
] | null |
NCT06127407 | [
{
"id_field": "org_study_id",
"id_value": [
"CL3-95031-007"
]
},
{
"id_field": "acronym",
"id_value": [
"CHONQUER"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CL3-95031-007"
]
},
{
"id_field": "bridge_id",
"id_value": [
"JPRN-jRCT... | https://clinicaltrials.gov/study/NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic co... | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | [
{
"description": "Provided as tablets, taken orally as two 250mg tablets once daily.",
"name": "Ivosidenib 500mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Provided as tablets, taken orally once daily.",
"name": "Placebo",
"normalized... | [
{
"design_group_description": "Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years).",
"design_group_title": "Ivosidenib",
... | [
"Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen"
] | [
"Servier Bio-Innovation LLC"
] | [
"Institut de Recherches Intern Servier"
] | [
[
{
"name": "艾伏尼布",
"lang": "CN"
},
{
"name": "Ivosidenib",
"lang": "EN"
},
{
"name": "イボシデニブ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "4425e2225a58a022a2a054458400999e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "898022d2a353282302249edead0920d8",
"s... |
NCT02187471 | [
{
"id_field": "org_study_id",
"id_value": [
"DS5565-A-E310"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2013-005162-20"
]
}
] | https://clinicaltrials.gov/study/NCT02187471 | Treatment of Pain Associated With Fibromyalgia | The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo.<br/>Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 h... | A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia | [
{
"description": "DS-5565 15 mg QD or BID; tablet for oral use",
"name": "DS-5565",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mirogabalin"
],
"type": "Drug"
},
{
"description": "Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 ... | [
{
"design_group_description": "Participants take one each of placebo tablet and capsule, twice daily (BID)",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"inter... | [
"Pain Associated With Fibromyalgia"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
"Syneos Health, Inc."
] | [
[
{
"name": "苯磺酸美洛加巴林",
"lang": "CN"
},
{
"name": "Mirogabalin Besilate",
"lang": "EN"
},
{
"name": "ミロガバリンベシル酸塩",
"lang": "JP"
}
]
] | null |
NCT06795178 | [
{
"id_field": "org_study_id",
"id_value": [
"FP014C-24-001"
]
},
{
"id_field": "acronym",
"id_value": [
"KATANA E3M"
]
}
] | https://clinicaltrials.gov/study/NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer | This is a study in male patients with advanced prostate cancer who are eligible for androgen ablation therapy. The study duration will be up to 26 weeks.<br/>Eligibility will be assessed during a screening period of up to 28 days. Up to 2 doses of a long-acting FP-014, 11.25 mg formulation will be given to the patients... | A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg (Triptorelin Mesylate Injection, 11.25 mg) in Patients With Advanced Prostate Cancer (KATANA E3M) | [
{
"description": "11.25 mg in a prefilled, ready-to-use, long-acting formulation",
"name": "FP-014",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Triptorelin Mesylate"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Each patient will receive 2 single doses of FP-014, 11.25 mg administered as SC injections. The two injections of the study drug will be administered 12 weeks apart; one injection at Baseline (Visit 2/Day 0/Week 1), and one at Visit 13 (Day 84/Week 12) to achieve castrate serum te... | [
"Prostate Cancer"
] | [
"Foresee Pharmaceuticals Co., Ltd."
] | [
"QPS Holdings LLC"
] | [
[
{
"name": "双羟萘酸曲普瑞林",
"lang": "CN"
},
{
"name": "Triptorelin Pamoate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "KATANA E3M"
}
] |
NCT03073018 | [
{
"id_field": "org_study_id",
"id_value": [
"METc 97/10/172"
]
},
{
"id_field": "acronym",
"id_value": [
"PREVEND-IT"
]
}
] | https://clinicaltrials.gov/study/NCT03073018 | Prevention of Renal and Vascular Endstage Disease Intervention Trial | The Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) was designed to determine whether intervention with the angiotensin-converting enzyme (ACE) inhibitor fosinopril and/or the hydroxymethylglutaryl coenzyme A reductase inhibitor pravastatin reduced cardiovascular and renal events in no... | Prevention of Renal and Vascular Endstage Disease Intervention Trial | [
{
"description": "oral administration, capsules",
"name": "Fosinopril",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Monopril"
],
"type": "Drug"
},
{
"description": "oral administration, capsules",
"name": "Pravastatin",
"normalized_type": "3d... | [
{
"design_group_description": "Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years",
"design_group_title": "Fosinopril + Pravastatin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Microalbuminuria",
"Cardiovascular Diseases",
"Renal Disease"
] | [
"Universitair Medisch Centrum Groningen"
] | [
"Nierstichting Nederland"
] | [
[
{
"name": "普伐他汀钠",
"lang": "CN"
},
{
"name": "Pravastatin Sodium",
"lang": "EN"
},
{
"name": "プラバスタチンナトリウム",
"lang": "JP"
}
],
[
{
"name": "福辛普利钠",
"lang": "CN"
},
{
"name": "Fosinopril Sodium",
"lang": "EN"
}
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PREVEND-IT"
},
{
"identifier_source": [
{
"code": "9a4895a99ea8d59320eae92e942de52a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT00135876 | [
{
"id_field": "org_study_id",
"id_value": [
"524E-CVD-0056-013"
]
}
] | https://clinicaltrials.gov/study/NCT00135876 | Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients | In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE. | A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) | [
{
"name": "dalteparin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Venous Thromboembolism",
"Brain Tumors"
] | [
"Ontario Clinical Oncology Group"
] | [
"Pfizer Inc."
] | [
[
{
"name": "达肝素钠",
"lang": "CN"
},
{
"name": "Dalteparin Sodium",
"lang": "EN"
},
{
"name": "ダルテパリンナトリウム",
"lang": "JP"
}
]
] | null |
NCT04656613 | [
{
"id_field": "org_study_id",
"id_value": [
"06-Gam-COVID-Vac-2020"
]
},
{
"id_field": "acronym",
"id_value": [
"SPUTNIK-UAE"
]
}
] | https://clinicaltrials.gov/study/NCT04656613 | A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE | This study is randomized, double-blind (blinded for the trial subject and the study physician), placebo-controlled trial in the parallel assignment of the immunogenicity, and safety of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection pr... | A Phase III, Randomized, Double -Blind, Placebo-controlled Trial to Evaluate Immunogenicity and Safety of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection in the United Arab Emirates | [
{
"description": "the Gam-COVID-Vac is combined 2 -component vector vaccine against the SARS-СoV-2-induced coronavirus infection",
"name": "Gam-COVID-Vac",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Sputnik V"
],
"type": "Biological"
},
{
"descripti... | [
{
"design_group_description": "a study group of 750 subjects receiving the Gam-COVID-Vac combined vector vaccine against the SARS-СoV-2-induced coronavirus infection",
"design_group_title": "Vaccine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf... | [
"Covid19",
"SARS-CoV Infection"
] | [
"Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation"
] | [
"Pdc Cro"
] | [
[
{
"name": "Gam-COVID-Vac",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SPUTNIK-UAE"
}
] |
NCT04322123 | [
{
"id_field": "org_study_id",
"id_value": [
"Brazil COVID Coalition I Trial"
]
},
{
"id_field": "acronym",
"id_value": [
"Coalition-I"
]
}
] | https://clinicaltrials.gov/study/NCT04322123 | Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19) | Coronavirus (COVID-19) is a somewhat new and recognized infectious disease that is now spreading to several countries in the world, including Brazil. Hydroxychloroquine and azithromycin may be useful for treating those patients.<br/>COALITION I study aims to compared standard of care, hydroxychloroquine plus azithromyc... | An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients | [
{
"description": "Hydroxychloroquine 400 mg BID",
"name": "Hydroxychloroquine Oral Product",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day",
"name": "Hydroxychloroquine + azithromy... | [
{
"design_group_description": "Hydroxychloroquine after randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 07 days.",
"design_group_title": "Hydroxychloroquine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"Coronavirus Infections"
] | [
"Associacao Beneficente Siria"
] | [
"Hospital Israelita Albert Einstein",
"EMS SA (Brazil)",
"Sociedade Beneficiente de Senhoras Hospital Sírio Libanês"
] | [
[
{
"name": "硫酸羟氯喹",
"lang": "CN"
},
{
"name": "Hydroxychloroquine Sulfate",
"lang": "EN"
},
{
"name": "ドロキシクロロキン硫酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "222aa42534d44a5230a3043e9d5e252e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "COALITION II"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
... |
NCT02135510 | [
{
"id_field": "org_study_id",
"id_value": [
"2011/366"
]
},
{
"id_field": "acronym",
"id_value": [
"MEDEA"
]
}
] | https://clinicaltrials.gov/study/NCT02135510 | MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy | In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (... | MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial | [
{
"name": "metoclopramide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "dexamethason",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "palonosetron",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_title": "metoclopramide",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_name": "metoclopramide",
"intervention_type": "Drug",
"normalized_intervention_ty... | [
"Solid Tumors"
] | [
"Stichting Onderzoek Cancer Center Amsterdam"
] | [
"Rijnstate",
"Ziekenhuis Amstelland",
"Noordwest Ziekenhuisgroep"
] | [
[
{
"name": "盐酸甲氧氯普胺",
"lang": "CN"
},
{
"name": "Metoclopramide Hydrochloride",
"lang": "EN"
},
{
"name": "塩酸メトクロプラミド",
"lang": "JP"
}
],
[
{
"name": "盐酸帕洛诺司琼",
"lang": "CN"
},
{
"name": "Palonosetron hydrochloride",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MEDEA"
}
] |
NCT01169259 | [
{
"id_field": "org_study_id",
"id_value": [
"2009P-001217"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01CA138962"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R0... | https://clinicaltrials.gov/study/NCT01169259 | Vitamin D and Omega-3 Trial (VITAL) | The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have ... | Vitamin D and Omega-3 Trial (VITAL) | [
{
"description": "Vitamin D3 (cholecalciferol), 2000 IU per day.",
"name": "vitamin D3",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"other_name": [
"cholecalciferol"
],
"type": "Dietary Supplement"
},
{
"description": "Omacor, one 1-gram capsule per day. Each capsul... | [
{
"design_group_title": "Vitamin D + fish oil",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 mill... | [
"Cancer",
"Cardiovascular Disease"
] | [
"The Brigham & Women's Hospital, Inc."
] | [
"Pharmavite LLC",
"National Heart, Lung & Blood Institute",
"National Cancer Institute",
"National Institute of Neurological Disorders & Stroke",
"National Center For Complementary & Integrative Health",
"Pronova BioPharma ASA",
"BASF Corp.",
"Office of Dietary Supplements"
] | [
[
{
"name": "ω-3酸乙酯(Trygg Pharma AS)",
"lang": "CN"
},
{
"name": "Omega-3-acid ethyl esters(Trygg Pharma AS)",
"lang": "EN"
}
],
[
{
"name": "维生素D3",
"lang": "CN"
},
{
"name": "Colecalciferol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2852e95de2aa454852a90208e55a254a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "28552905aee00a5283954a2203848355",
"s... |
NCT02174627 | [
{
"id_field": "org_study_id",
"id_value": [
"D5740C00001"
]
}
] | https://clinicaltrials.gov/study/NCT02174627 | Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis | The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis | [
{
"description": "The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.",
"name": "Roxadustat",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "The initial study drug d... | [
{
"design_group_title": "Roxadustat",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adj... | [
"Anemia"
] | [
"AstraZeneca PLC"
] | [
"Kyntra Bio, Inc."
] | [
[
{
"name": "罗沙司他",
"lang": "CN"
},
{
"name": "Roxadustat",
"lang": "EN"
},
{
"name": "ロキサデュスタット",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "8e83deedaa80aeee4aea03e5ad9e258a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e5aa8a8549e228320d53e23032585852",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT00455156 | [
{
"id_field": "org_study_id",
"id_value": [
"CCN006"
]
},
{
"id_domain": "NICHD",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CCN006"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CCN006;CCN006"
]
}
] | https://clinicaltrials.gov/study/NCT00455156 | Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring | The purpose of this study is to evaluate the one-year data on the contraceptive efficacy and safety of the 150/15 NES/EE CVR as the basis for regulatory approvals of this CVR as a new delivery system for contraception. | A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone® and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR) | [
{
"description": "150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.",
"name": "150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.",
"design_group_title": "150/15 NES/EE CVR",
"design_group_type": "Experimental",
"design_group_type_no... | [
"Contraception"
] | [
"Premier Research"
] | [
"The Population Council, Inc.",
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "醋酸烯诺孕酮/炔雌醇",
"lang": "CN"
},
{
"name": "Ethinyl Estradiol/Segesterone Acetate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "5e5520a2394e2deedd4aa58aea358ad2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8a4a025ae5ae8229eaa9a040a9282225",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "pha... |
NCT00629135 | [
{
"id_field": "org_study_id",
"id_value": [
"MHH-MW-01"
]
},
{
"id_field": "acronym",
"id_value": [
"MEMO"
]
}
] | https://clinicaltrials.gov/study/NCT00629135 | Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses | The study is contemplating the antibiotic therapy of intraabdominal abscesses. These abscesses are a serious problem in surgical practice. Associated pathophysiologic effects as for example peritonitis may become life threatening or may lead to extended periods of morbidity with prolonged hospitalization.<br/>The objec... | Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses | [
{
"description": "Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously ... | [
{
"design_group_description": "For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by... | [
"Abscess, Intra-Abdominal"
] | [
"Hannover Medical School"
] | [
"Bayer AG"
] | [
[
{
"name": "甲硝唑",
"lang": "CN"
},
{
"name": "Metronidazole",
"lang": "EN"
},
{
"name": "メトロニダゾール",
"lang": "JP"
}
],
[
{
"name": "盐酸莫西沙星",
"lang": "CN"
},
{
"name": "Moxifloxacin Hydrochloride",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MEMO"
}
] |
NCT07181382 | [
{
"id_field": "org_study_id",
"id_value": [
"GB002-3201"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2025-521777-13-00"
]
},
{
"id_field": "acronym",
"id_value": [
"SERANATA"
]
},
{
"id_field": "seco... | https://clinicaltrials.gov/study/NCT07181382 | Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The primary objective of the PCP is to evaluate the effect of seralutinib on improving exercise capacity in subjects with World Health Organization (WHO) Group 3... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy | [
{
"description": "Matching capsule containing placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Capsule containing seralutinib",
"name": "Seralutinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"ty... | [
{
"design_group_description": "Placebo inhaled orally twice daily (BID) for 24 weeks in PCP. Subjects randomized to the placebo treatment group in the PCP will receive seralutinib in LTE.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id":... | [
"Pulmonary Hypertension Associated With Interstitial Lung Disease"
] | [
"Gossamer Bio, Inc."
] | [
"CHIESI Farmaceutici SpA"
] | [
[
{
"name": "Seralutinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SERANATA"
}
] |
NCT03277313 | [
{
"id_field": "org_study_id",
"id_value": [
"161503"
]
}
] | https://clinicaltrials.gov/study/NCT03277313 | Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects | The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to <16 years) participants with primary immunodeficiency disease (PIDD). | Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases | [
{
"description": "Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)",
"name": "HYQVIA",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"IGI 10% with rHuPH20"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Pediatric participants with PIDD who were on IV or non-HYQVIA SC treatment with immunoglobulin were enrolled and treated with HYQVIA SC with a dose or interval ramp-up period of up to six weeks. HYQVIA dose was planned to be equivalent to 100% (± 5%) of pre-study treatment. Dose f... | [
"Primary Immunodeficiency Diseases (PID)"
] | [
"Baxalta, Inc."
] | [
"Baxalta Innovations GmbH"
] | [
[
{
"name": "人免疫球蛋白 (Takeda)",
"lang": "CN"
},
{
"name": "Human normal immunoglobulin(Takeda)",
"lang": "EN"
},
{
"name": "人免疫グロブリン (Takeda)",
"lang": "JP"
}
]
] | null |
NCT00002545 | [
{
"id_field": "org_study_id",
"id_value": [
"RTOG-9305"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CDR0000063286"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CDR0000063286;RTOG-9305"
]
}
] | https://clinicaltrials.gov/study/NCT00002545 | Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme | RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.<br/>PURPOSE: Randomized phase III trial to study the effectiveness of radia... | A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME | [
{
"name": "carmustine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "low-LET photon therapy",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"type": "Radiation"
}
] | null | [
"Brain and Central Nervous System Tumors"
] | [
"Radiation Therapy Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "卡莫司汀",
"lang": "CN"
},
{
"name": "Carmustine",
"lang": "EN"
},
{
"name": "カルムスチン",
"lang": "JP"
}
]
] | null |
NCT00252720 | [
{
"id_field": "org_study_id",
"id_value": [
"D2453C00046"
]
},
{
"id_field": "secondary_id",
"id_value": [
"DIRECT"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SH-AHM-0046"
]
},
{
"id_field": "acronym",
"id_value": [
"DIRECT"
... | https://clinicaltrials.gov/study/NCT00252720 | DIabetic Retinopathy Candesartan Trials. | The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.<br/>The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clini... | DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy. | [
{
"description": "32 mg oral tablet",
"name": "candesartan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ATACAND"
],
"type": "Drug"
}
] | [
{
"design_group_description": "candesartan cilexetil 32 mg once daily",
"design_group_title": "candesartan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "32 mg oral table... | [
"Type 1 Diabetes"
] | [
"AstraZeneca PLC"
] | [
"Takeda Pharmaceutical Co., Ltd."
] | [
[
{
"name": "坎地沙坦酯",
"lang": "CN"
},
{
"name": "Candesartan Cilexetil",
"lang": "EN"
},
{
"name": "カンデサルタン シレキセチル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "92e82588ade2e28ae55423a43a25543e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e892eeaa3d550e05aa3dee4dee2e235a",
"s... |
NCT03128905 | [
{
"id_field": "org_study_id",
"id_value": [
"RC-P0050"
]
},
{
"id_field": "acronym",
"id_value": [
"COLCHICORT"
]
}
] | https://clinicaltrials.gov/study/NCT03128905 | Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis | Chondrocalcinosis, recently renamed the calcium pyrophosphate deposition (CPPD) disease, is a very frequent affection of the elderly and causes very painful arthritis.<br/>International recommendations for the treatment of patients suffering from CPPD are based upon rare studies, not randomized, with small samples, and... | Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety | [
{
"description": "International non-proprietary name: Colchicine<br/>Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.<br/>Composition :<br/>Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesi... | [
{
"design_group_description": "Patients assigned to this group will receive the Colchicine opocalcium 1mg treatment.",
"design_group_title": "Colchicine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Chondrocalcinosis"
] | [
"Université Catholique de Lille"
] | [
"Hopital Lariboisière",
"Bichat-Claude Bernard Hospital",
"Centre Hospitalier d'Armentières",
"Centre Hospitalier Universitaire de Lille"
] | [
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0222ae8a29e230de5e35a25aa300830e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "de890a950e00ea202d435e9e3854a2e5",
"s... |
NCT04401748 | [
{
"id_field": "org_study_id",
"id_value": [
"M15-954"
]
},
{
"id_domain": "EU CT",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2023-507153-16-00"
]
},
{
"id_field": "acronym",
"id_value": [
"Verona"
]
}
] | https://clinicaltrials.gov/study/NCT04401748 | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death fro... | A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) | [
{
"description": "Tablet: Oral",
"name": "Venetoclax",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ABT-199",
"GDC-0199",
"Venclexta"
],
"type": "Drug"
},
{
"description": "Subcutaneous (SC) or Intravenous (IV) injection",
"name": "Aza... | [
{
"design_group_description": "Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.",
"design_group_title": "Arm 1: Venetoclax + Azacitidine (AZA)",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Myelodysplastic Syndrome (MDS)"
] | [
"AbbVie, Inc."
] | [
"Genentech, Inc."
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "阿扎胞苷",
"lang": "CN"
},
{
"name": "Azacitidine",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8980a83a222839d8e5ad90e489e5d509",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a2d38238928888daee9de8e538aea5a8",
"s... |
NCT00026286 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000069015"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-2193"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-P01-0194"
]
}
] | https://clinicaltrials.gov/study/NCT00026286 | Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer | RATIONALE: Hormone replacement therapy may be effective in managing the hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer.<br/>PURPOSE: Randomized phase III trial to determine the effectiveness of hormone replacement therapy in managing hot flashes and/or vaginal ... | A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen | [
{
"name": "conjugated estrogens",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "medroxyprogesterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
... | null | [
"Breast Cancer",
"Hot Flashes",
"Menopausal Symptoms"
] | [
"Eastern Cooperative Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "醋酸甲羟孕酮",
"lang": "CN"
},
{
"name": "Medroxyprogesterone Acetate",
"lang": "EN"
},
{
"name": "メドロキシプロゲステロン酢酸エステル",
"lang": "JP"
}
],
[
{
"name": "结合雌激素",
"lang": "CN"
},
{
"name": "Estrogens, Conjugated",
... | null |
NCT02914535 | [
{
"id_field": "org_study_id",
"id_value": [
"GS-US-418-3899"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2016-002765-58"
]
},
{
"id_field": "acronym",
"id_value": [
"SELECTIONLTE"
]
}
] | https://clinicaltrials.gov/study/NCT02914535 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC). | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis | [
{
"description": "Tablet(s) administered orally once daily",
"name": "Filgotinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"GLPG0634",
"GS-6034"
],
"type": "Drug"
},
{
"description": "Tablet(s) administered orally once daily",
"name": "P... | [
{
"design_group_description": "Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 336 weeks",
"design_group_title": "Filgotinib 200 mg (blinded dosing)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Ulcerative Colitis"
] | [
"Alfasigma SpA"
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "非戈替尼",
"lang": "CN"
},
{
"name": "Filgotinib Maleate",
"lang": "EN"
},
{
"name": "フィルゴチニブマレイン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "55928de82088e22e5e958250d2d52a84",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "85eeaa8aa5238258e5a998e94820aee3",
"s... |
NCT05171049 | [
{
"id_field": "org_study_id",
"id_value": [
"ANT-007"
]
},
{
"id_domain": "EUCT number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2023-509569-19-00"
]
},
{
"id_domain": "Novartis",
"id_field": "secondary_id",
"id_type":... | https://clinicaltrials.gov/study/NCT05171049 | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE | This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER) | A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE | [
{
"description": "Abelacimab 150 mg",
"name": "Abelacimab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"MAA868"
],
"type": "Biological"
},
{
"description": "Apixaban 10 mg followed by 5 mg",
"name": "Apixaban",
"normalized_type": "3d1aa88261d... | [
{
"design_group_description": "Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously",
"design_group_title": "Abelacimab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention"... | [
"Venous Thromboembolism",
"Deep Venous Thrombosis",
"Pulmonary Embolism"
] | [
"Anthos Therapeutics, Inc."
] | [
"Novartis Pharmaceuticals Canada, Inc."
] | [
[
{
"name": "Abelacimab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ASTER"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.